Prefix: : <http://www.genomic-cds.org/ont/structured_product_label_annotations.owl#>
Prefix: oa: <http://www.w3.org/ns/oa#>
Prefix: owl: <http://www.w3.org/2002/07/owl#>
Prefix: rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>
Prefix: spl: <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#>
Prefix: xml: <http://www.w3.org/XML/1998/namespace>
Prefix: xsd: <http://www.w3.org/2001/XMLSchema#>
Prefix: rdfs: <http://www.w3.org/2000/01/rdf-schema#>



Ontology: <http://www.genomic-cds.org/ont/structured_product_label_annotations.owl>


AnnotationProperty: <http://semanticscience.org/resource/SIO_000628>

    Annotations: 
        <http://purl.org/dc/terms/description> "refers to is a relation between one entity and the entity that it makes reference to.",
        rdfs:label "refers to"
    
    Annotations: 
        <http://purl.org/dc/terms/description> "refers to is a relation between one entity and the entity that it makes reference to.",
        rdfs:label "refers to"
    
    
AnnotationProperty: oa:hasTarget

    
AnnotationProperty: <http://purl.org/dc/terms/description>

    
AnnotationProperty: spl:PharmacodynamicImpact

    Annotations: 
        <http://purl.org/dc/terms/description> "Information on the pharmacodynamic impact of a pharmacogenomic biomarker.",
        rdfs:label "PharmacodynamicImpact"
    
    Annotations: 
        <http://purl.org/dc/terms/description> "Information on the pharmacodynamic impact of a pharmacogenomic biomarker.",
        rdfs:label "PharmacodynamicImpact"
    
    
AnnotationProperty: <http://purl.org/dc/terms/date>

    
AnnotationProperty: spl:PharmacokineticImpact

    Annotations: 
        <http://purl.org/dc/terms/description> "Information on the pharmacokinetic impact of a pharmacogenomic biomarker.",
        rdfs:label "PharmacokineticImpact"
    
    Annotations: 
        <http://purl.org/dc/terms/description> "Information on the pharmacokinetic impact of a pharmacogenomic biomarker.",
        rdfs:label "PharmacokineticImpact"
    
    
AnnotationProperty: <http://purl.org/dc/terms/publisher>

    
AnnotationProperty: spl:SPLSection

    Annotations: 
        <http://purl.org/dc/terms/description> "The Structured Product Label section that a proof-of-concept claim mapping is thought to be relevant to.",
        rdfs:label "SPLSection"
    
    Annotations: 
        <http://purl.org/dc/terms/description> "The Structured Product Label section that a proof-of-concept claim mapping is thought to be relevant to.",
        rdfs:label "SPLSection"
    
    
AnnotationProperty: <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>

    
AnnotationProperty: spl:VariantFrequency

    Annotations: 
        <http://purl.org/dc/terms/description> "The frequency or proportion at which a variant occurs in a specific population.",
        rdfs:label "VariantFrequency"
    
    Annotations: 
        <http://purl.org/dc/terms/description> "The frequency or proportion at which a variant occurs in a specific population.",
        rdfs:label "VariantFrequency"
    
    
AnnotationProperty: oa:postfix

    
AnnotationProperty: oa:annotatedBy

    
AnnotationProperty: spl:DoseSelectionRecommendation

    Annotations: 
        <http://purl.org/dc/terms/description> "A recommendation regarding drug dosing that is related to the biomarker.",
        rdfs:label "DoseSelectionRecommendation"
    
    Annotations: 
        <http://purl.org/dc/terms/description> "A recommendation regarding drug dosing that is related to the biomarker.",
        rdfs:label "DoseSelectionRecommendation"
    
    
AnnotationProperty: oa:hasSelector

    Annotations: 
        <http://purl.org/dc/terms/description> "The relationship between a oa:SpecificResource and a oa:Selector. See http://www.w3.org/ns/oa#hasSelector",
        rdfs:label "hasSelector"
    
    Annotations: 
        <http://purl.org/dc/terms/description> "The relationship between a oa:SpecificResource and a oa:Selector. See http://www.w3.org/ns/oa#hasSelector",
        rdfs:label "hasSelector"
    
    
AnnotationProperty: oa:motivatedBy

    
AnnotationProperty: oa:hasBody

    
AnnotationProperty: <http://purl.org/dc/terms/title>

    
AnnotationProperty: oa:item

    
AnnotationProperty: <http://purl.org/dc/terms/creator>

    
AnnotationProperty: <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>

    
AnnotationProperty: oa:prefix

    
AnnotationProperty: spl:MonitoringRecommendation

    Annotations: 
        rdfs:label "MonitoringRecommendation",
        <http://purl.org/dc/terms/description> "A recommendation regarding monitoring that is related to the biomarker."
    
    Annotations: 
        <http://purl.org/dc/terms/description> "A recommendation regarding monitoring that is related to the biomarker.",
        rdfs:label "MonitoringRecommendation"
    
    
AnnotationProperty: rdfs:label

    
AnnotationProperty: spl:DrugSelectionRecommendation

    Annotations: 
        <http://purl.org/dc/terms/description> "A recommendation regarding drug selection that is related to the biomarker.",
        rdfs:label "DrugSelectionRecommendation"
    
    Annotations: 
        <http://purl.org/dc/terms/description> "A recommendation regarding drug selection that is related to the biomarker.",
        rdfs:label "DrugSelectionRecommendation"
    
    
AnnotationProperty: <http://purl.org/dc/terms/license>

    
AnnotationProperty: rdfs:seeAlso

    
AnnotationProperty: oa:hasSource

    
AnnotationProperty: spl:TestRecommendation

    Annotations: 
        rdfs:label "TestRecommendation",
        <http://purl.org/dc/terms/description> "A recommendation regarding testing that is related to the biomarker."
    
    Annotations: 
        <http://purl.org/dc/terms/description> "A recommendation regarding testing that is related to the biomarker.",
        rdfs:label "TestRecommendation"
    
    
AnnotationProperty: oa:exact

    
AnnotationProperty: <http://semanticscience.org/resource/SIO_000563>

    Annotations: 
        <http://purl.org/dc/terms/description> "describes is a relation between one entity and another entity that it provides a description (detailed account of)",
        rdfs:label "describes"
    
    Annotations: 
        <http://purl.org/dc/terms/description> "describes is a relation between one entity and another entity that it provides a description (detailed account of)",
        rdfs:label "describes"
    
    
AnnotationProperty: oa:onResource

    
AnnotationProperty: oa:annotatedAt

    
Datatype: xsd:date

    
Datatype: rdf:PlainLiteral

    
Class: oa:SpecificResource

    Annotations: 
        rdfs:label "SpecificResource",
        <http://purl.org/dc/terms/description> "A resource identifies part of another Source resource, a particular representation of a resource, a resource with styling hints for renders, or any combination of these. See http://www.w3.org/ns/oa#SpecificResource"
    
    
Class: spl:PharmacogenomicsStatement

    Annotations: 
        rdfs:label "PharmacogenomicsStatement",
        <http://purl.org/dc/terms/description> "A clinical statement that describes: drug exposure and clinical response variability, risk for adverse events, genotype-specific dosing, mechanisms of drug action, and/or polymorphic drug target and disposition genes. See <http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm>"
    
    
Class: oa:TextQuoteSelector

    Annotations: 
        <http://purl.org/dc/terms/description> "A Selector that describes a textual segment by means of quoting it, plus passages before or after it. See http://www.w3.org/ns/oa#TextQuoteSelector",
        rdfs:label "TextQuoteSelector"
    
    
Class: <http://purl.org/dc/dcmitype/Collection>

    Annotations: 
        <http://purl.org/dc/terms/description> "A collection is described as a group; its parts may also be separately described. See http://dublincore.org/documents/dcmi-type-vocabulary/#H7",
        rdfs:label "Collection"
    
    
Class: spl:SPLConstrainedTarget

    Annotations: 
        <http://purl.org/dc/terms/description> "A constrained target for Structured Product Labeling - all instances must have an SPL set id.",
        rdfs:label "SPLConstrainedTarget"
    
    
Class: oa:Annotation

    Annotations: 
        <http://purl.org/dc/terms/description> "Typically an Annotation has a single Body (oa:hasBody), which is the comment or other descriptive resource, and a single Target (oa:hasTarget) that the Body is somehow 'about'. The Body provides the information which is annotating the Target. See  http://www.w3.org/ns/oa#Annotation",
        rdfs:label "Annotation"
    
    
Individual: <urn:uuid:51a1c204-1d9f-4956-a9df-ea178aeec2bb>

    Annotations: 
        oa:prefix "DOSAGE AND ADMINISTRATION ",
        oa:postfix " Renal Homotransplantation The dose of azathioprin",
        oa:exact "TPMT TESTING CANNOT SUBSTITUTE FOR COMPLETE BLOOD COUNT (CBC) MONITORING IN PATIENTS RECEIVING AZATHIOPRINE TABLETS. TPMT genotyping or phenotyping can be used to identify patients with absent or reduced TPMT activity. Patients with low or absent TPMT activity are at an increased risk of developing severe, life-threatening myelotoxicity from azathioprine tablets if conventional doses are given. Physicians may consider alternative therapies for patients who have low or absent TPMT activity (homozygous for non-functional alleles). Azathioprine tablets should be administered with caution to patients having one non-functional allele (heterozygous) who are at risk for reduced TPMT activity that may lead to toxicity if conventional doses are given. Dosage reduction is recommended in patients with reduced TPMT activity. Early drug discontinuation may be considered in patients with abnormal CBC results that do not respond to dose reduction."
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: spl:pharmgx-spl-annotation-item-19

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-19>,
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasTarget <urn:uuid:56ee2f99-5a66-4839-9a21-0db01be54fd5>
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-18

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-18>,
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasTarget <urn:uuid:0f334c36-0d0d-45c6-a84b-ebcbffa95420>
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-17

    Annotations: 
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-17>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:hasTarget <urn:uuid:9d536abb-5eb3-4ae7-9e1e-cebdea9a36b4>,
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-16

    Annotations: 
        oa:hasTarget <urn:uuid:cc558dbc-ff13-4097-a348-6d6ca7c2079f>,
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-16>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-15

    Annotations: 
        oa:hasTarget <urn:uuid:bee03e84-6eec-413a-86f9-8c2e14d60cf8>,
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-15>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-14

    Annotations: 
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-14>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasTarget <urn:uuid:85f68655-42ae-482f-93f5-e5809f810959>
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-13

    Annotations: 
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-13>,
        oa:hasTarget <urn:uuid:b9dd7291-c77b-4b82-8a60-cef55c9a863d>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-12

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:hasTarget <urn:uuid:cf8f868b-9b69-4de9-a05a-5378a1ad99ef>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-12>
    
    Types: 
        oa:Annotation
    
    
Individual: <urn:uuid:183fae1a-62c5-48b1-8a74-24c9bac2a7cb>

    Annotations: 
        oa:exact "Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir. Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of hypersensitivity reaction. Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir. HLA-B*5701-negative patients may develop a suspected hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients. Regardless of HLA-B*5701 status, permanently discontinue EPZICOM if hypersensitivity cannot be ruled out, even when other diagnoses are possible. Following a hypersensitivity reaction to abacavir, NEVER restart EPZICOM or any other abacavir-containing product because more severe symptoms can occur within hours and may include life-threatening hypotension and death.",
        oa:postfix " Reintroduction of EPZICOM or any other abacavir-c",
        oa:prefix "soon as a hypersensitivity reaction is suspected. "
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:89e91a6c-01c4-49f8-947c-3f7578772c70>

    Annotations: 
        oa:exact "Citalopram causes dose-dependent QTc prolongation, an ECG abnormality that has been associated with torsade de pointes (TdP), ventricular tachycardia, and sudden death, all of which have been observed in postmarketing reports for citalopram. Individually corrected QTc (QTcNi) interval was evaluated in a randomized, placebo and active (moxifloxacin 400 mg) controlled cross-over, escalating multiple-dose study in 119 healthy subjects. The maximum mean (upper bound of the 95% one-sided confidence interval) difference from placebo were 8.5 (10.8) and 18.5 (21.0) msec for 20 mg and 60 mg citalopram, respectively. Based on the established exposure-response relationship, the predicted QTcNi change from placebo (upper bound of the 95% one-sided confidence interval) under the Cmax for the dose of 40 mg is 12.6 (14.3) msec. Because of the risk of QTc prolongation at higher citalopram doses, it is recommended that citalopram should not be given at doses above 40 mg/day. It is recommended that citalopram should not be used in patients with congenital long QT syndrome, bradycardia, hypokalemia or hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure. Citalopram should also not be used in patients who are taking other drugs that prolong the QTc interval. Such drugs include Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications, antipsychotic medications (e.g., chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to prolong the QTc interval (e.g., pentamidine, levomethadyl acetate, methadone). The citalopram dose should be limited in certain populations. The maximum dose should be limited to 20 mg/day in patients who are CYP2C19 poor metabolizers or those patients who may be taking concomitant cimetidine or another CYP2C19 inhibitor, since higher citalopram exposures would be expected. The maximum dose should also be limited to 20 mg/day in patients with hepatic impairment and in patients who are greater than 60 years of age because of expected higher exposures.",
        oa:prefix " overdose. QT-Prolongation and Torsade de Pointes ",
        oa:postfix " Electrolyte and/or ECG monitoring is recommended "
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:1202299d-581a-4ff6-ac7a-494368c7e30a>

    Annotations: 
        oa:postfix " 18 Maintenance Most patients are satisfactorily m",
        oa:prefix "and is associated with a higher risk of bleeding. ",
        oa:exact "Initial Dosage The dose of warfarin sodium tablets must be individualized by monitoring the PT/INR. Not all factors causing warfarin dose variability are known. The maintenance dose needed to achieve a target PT/INR is influenced by: Clinical factors including age, race, body weight, sex, concomitant medications, and comorbidities and Genetic factors (CYP2C9 and VKORC1 genotypes). Select the starting dose based on the expected maintenance dose, taking into account the above factors. Routine use of loading doses is not recommended as this may increase hemorrhagic and other complications and does not offer more rapid protection against clot formation. If the patient’s CYP2C9 and VKORC1 genotypes are not known, the initial dose of warfarin sodium tablets is usually 2 to 5 mg per day. Modify this dose based on consideration of patient-specific clinical factors. Consider lower initiation doses for elderly and/or debilitated patients (see CLINICAL PHARMACOLOGY and PRECAUTIONS). The patient’s CYP2C9 and VKORC1 genotype information, when available, can assist in selection of the starting dose. Table 5 describes the range of stable maintenance doses observed in multiple patients having different combinations of CYP2C9 and VKORC1 gene variants. Consider these ranges in choosing the initial dose. In all patients, subsequent dosage adjustments must be made based on the results of PT/INR determinations.17,"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:df428acd-76dc-415c-87ed-f4d966f3ff2b>

    Annotations: 
        oa:hasSelector <urn:uuid:60698153-8e21-4917-a112-4cc020788bf0>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinicalPharmacology>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=217e52b5-3a7b-4bbe-af3c-b18de7d426c3>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:e7a0e43b-8915-4579-8336-ed61ed5d7dd4>

    Annotations: 
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/precautions>,
        oa:hasSelector <urn:uuid:352be581-2ab9-4f03-85ea-a9d6496179db>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=87315917-3e54-44e6-bb64-2f722501c11b>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:eee3489f-0618-47c1-8385-e4277010dced>

    Annotations: 
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/precautions>,
        oa:hasSelector <urn:uuid:d3019015-d24b-4a80-83b3-4b72216e2f2e>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=87315917-3e54-44e6-bb64-2f722501c11b>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: spl:pharmgx-spl-annotation-item-21

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:hasTarget <urn:uuid:86748657-bab4-48d1-80da-dac9242628ca>,
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-21>
    
    Types: 
        oa:Annotation
    
    
Individual: <urn:uuid:c5d898c2-b618-42ab-aeed-709bb377c86a>

    Annotations: 
        oa:exact "Warfarin sodium is a narrow therapeutic range (index) drug, and additional caution should be observed when warfarin sodium is administered to certain patients. Reported risk factors for bleeding include high intensity of anticoagulation (INR >4), age >65, highly variable INRs, history of gastrointestinal bleeding, hypertension, cerebrovascular disease, serious heart disease, anemia, malignancy, trauma, renal insufficiency, concomitant drugs (see PRECAUTIONS), and long duration of warfarin therapy. Identification of risk factors for bleeding and certain genetic variations in CYP2CP and VKORC1 in a patient may increase the need for more frequent INR monitoring and the use of lower warfarin doses (see CLINICAL PHARMACOLOGY, Pharmacokinetics, Metabolism and DOSAGE AND ADMINISTRATION). Bleeding is more likely to occur during the starting period and with a higher dose of warfarin sodium (resulting in a higher INR)",
        oa:postfix ". Intramuscular (IM) injections of concomitant med",
        oa:prefix "etion. Considerations for Increased Bleeding Risk "
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: spl:pharmgx-spl-annotation-item-22

    Annotations: 
        oa:hasTarget <urn:uuid:e7a0e43b-8915-4579-8336-ed61ed5d7dd4>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-22>,
        oa:annotatedAt "2013-03-13"^^xsd:date
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-20

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:hasTarget <urn:uuid:9e2cd2cc-9a25-47b6-8ace-33867495d9b2>,
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-20>
    
    Types: 
        oa:Annotation
    
    
Individual: <urn:uuid:5601264a-45a1-43ff-9256-0702d199c5df>

    Annotations: 
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7500c65e-9680-4719-b426-90a7162352c9>,
        oa:hasSelector <urn:uuid:7047bb6e-0cbc-4ecf-adbb-ee3dbead12d5>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinicalPharmacology>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:9db528e5-494b-4fa0-8251-26d67286feba>

    Annotations: 
        oa:exact "Identification of risk factors for bleeding and certain genetic variations in CYP2C9 and VKORC1 in a patient may increase the need for more frequent INR monitoring and the use of lower warfarin doses (see CLINICAL PHARMACOLOGY:PharmacokineticsMetabolismandDOSAGE AND ADMINISTRATION).",
        oa:prefix "ECAUTIONS) and long duration of warfarin therapy. ",
        oa:postfix " Bleeding is more likely to occur during the start"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:f04f09ba-0ac5-45b4-8ee8-ccafdaae09cf>

    Annotations: 
        oa:prefix "omy, axillary dissection, and breast irradiation. ",
        oa:exact "The estrogen- and progesterone-receptor values may help to predict whether adjuvant tamoxifen therapy is likely to be beneficial.",
        oa:postfix " Tamoxifen reduces the occurrence of contralateral"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: spl:pharmgx-spl-annotation-body-10

    Annotations: 
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "CLOPIDOGREL",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Clopidogrel>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2C19",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2C19>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>,
        spl:PharmacodynamicImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00758>
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-set-2

    Annotations: 
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-23>,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-22>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-2>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-69>,
        oa:onResource <file:///home/rdb20/Downloads/d2rq-0.8.1/linkedSPLs-dump.nt#structuredProductLabelMetadata/87315917-3e54-44e6-bb64-2f722501c11b>
    
    Types: 
        <http://purl.org/dc/dcmitype/Collection>
    
    
Individual: <urn:uuid:50dcc8f4-1991-4b87-973d-d143722f3c9d>

    Annotations: 
        oa:postfix " 18 Maintenance Most patients are satisfactorily m",
        oa:prefix "and is associated with a higher risk of bleeding. ",
        oa:exact "Initial Dosage The dose of warfarin sodium tablets must be individualized by monitoring the PT/INR. Not all factors causing warfarin dose variability are known. The maintenance dose needed to achieve a target PT/INR is influenced by: Clinical factors including age, race, body weight, sex, concomitant medications, and comorbidities and Genetic factors (CYP2C9 and VKORC1 genotypes). Select the starting dose based on the expected maintenance dose, taking into account the above factors. Routine use of loading doses is not recommended as this may increase hemorrhagic and other complications and does not offer more rapid protection against clot formation. If the patient’s CYP2C9 and VKORC1 genotypes are not known, the initial dose of warfarin sodium tablets is usually 2 to 5 mg per day. Modify this dose based on consideration of patient-specific clinical factors. Consider lower initiation doses for elderly and/or debilitated patients (see CLINICAL PHARMACOLOGY and PRECAUTIONS). The patient’s CYP2C9 and VKORC1 genotype information, when available, can assist in selection of the starting dose. Table 5 describes the range of stable maintenance doses observed in multiple patients having different combinations of CYP2C9 and VKORC1 gene variants. Consider these ranges in choosing the initial dose. In all patients, subsequent dosage adjustments must be made based on the results of PT/INR determinations.17,"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: spl:pharmgx-spl-annotation-set-3

    Annotations: 
        oa:onResource <file:///home/rdb20/Downloads/d2rq-0.8.1/linkedSPLs-dump.nt#structuredProductLabelMetadata/3d35df36-1a19-4559-91fe-252b7082295b>,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-24>,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-71>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-27>,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-3>,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-26>,
        oa:annotatedAt "2013-03-13"^^xsd:date
    
    Types: 
        <http://purl.org/dc/dcmitype/Collection>
    
    
Individual: spl:pharmgx-spl-annotation-set-4

    Annotations: 
        oa:onResource <file:///home/rdb20/Downloads/d2rq-0.8.1/linkedSPLs-dump.nt#structuredProductLabelMetadata/f1139e7f-2db9-4961-9da3-9b7f2088736f>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-28>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-4>
    
    Types: 
        <http://purl.org/dc/dcmitype/Collection>
    
    
Individual: spl:pharmgx-spl-annotation-set-5

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-29>,
        oa:onResource <file:///home/rdb20/Downloads/d2rq-0.8.1/linkedSPLs-dump.nt#structuredProductLabelMetadata/6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-55>,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-56>,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-5>
    
    Types: 
        <http://purl.org/dc/dcmitype/Collection>
    
    
Individual: <urn:uuid:b9712f8a-87a2-4080-9d33-95b3a0e50f05>

    Annotations: 
        oa:exact "Tamoxifen therapy to reduce the incidence of breast cancer may therefore not be appropriate for all women at high risk for breast cancer. Women who are considering tamoxifen therapy should consult their health care professional for an assessment of the potential benefits and risks prior to starting therapy for reduction in breast cancer incidence (see Table 3 in CLINICAL PHARMACOLOGY). Women should understand that tamoxifen reduces the incidence of breast cancer, but may not eliminate risk. Tamoxifen decreased the incidence of small estrogen receptor positive tumors, but did not alter the incidence of estrogen receptor negative tumors or larger tumors.",
        oa:postfix " In women with breast cancer who are at high risk ",
        oa:prefix "ory and on how she weighs the benefits and risks. "
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: spl:pharmgx-spl-annotation-set-1

    Annotations: 
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-53>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-45>,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-16>,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-46>,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-15>,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-52>,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-1>,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-66>,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-67>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:onResource <file:///home/rdb20/Downloads/d2rq-0.8.1/linkedSPLs-dump.nt#structuredProductLabelMetadata/fa3ed180-298a-4f9d-9d05-15182d7218bf>
    
    Types: 
        <http://purl.org/dc/dcmitype/Collection>
    
    
Individual: spl:pharmgx-spl-annotation-body-19

    Annotations: 
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00675>,
        spl:PharmacodynamicImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "ER_receptor",
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "TAMOXIFEN"
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: <urn:uuid:352be581-2ab9-4f03-85ea-a9d6496179db>

    Annotations: 
        oa:postfix ". Intramuscular (IM) injections of concomitant med",
        oa:exact "Considerations for Increased Bleeding Risk Warfarin sodium is a narrow therapeutic range (index) drug, and additional caution should be observed when warfarin sodium is administered to certain patients. Reported risk factors for bleeding include high intensity of anticoagulation (INR >4), age >65, highly variable INRs, history of gastrointestinal bleeding, hypertension, cerebrovascular disease, serious heart disease, anemia, malignancy, trauma, renal insufficiency, concomitant drugs (see PRECAUTIONS), and long duration of warfarin therapy. Identification of risk factors for bleeding and certain genetic variations in CYP2CP and VKORC1 in a patient may increase the need for more frequent INR monitoring and the use of lower warfarin doses (see CLINICAL PHARMACOLOGY, Pharmacokinetics, Metabolism and DOSAGE AND ADMINISTRATION). Bleeding is more likely to occur during the starting period and with a higher dose of warfarin sodium (resulting in a higher INR)",
        oa:prefix "erence with either their metabolism or excretion. "
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: spl:pharmgx-spl-annotation-set-7

    Annotations: 
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-50>,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-37>,
        oa:onResource <file:///home/rdb20/Downloads/d2rq-0.8.1/linkedSPLs-dump.nt#structuredProductLabelMetadata/7500c65e-9680-4719-b426-90a7162352c9>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-31>,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-7>
    
    Types: 
        <http://purl.org/dc/dcmitype/Collection>
    
    
Individual: spl:pharmgx-spl-annotation-set-6

    Annotations: 
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-36>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-6>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-30>,
        oa:onResource <file:///home/rdb20/Downloads/d2rq-0.8.1/linkedSPLs-dump.nt#structuredProductLabelMetadata/040d010a-b1b2-4db7-905d-8aa7f1bab0cd>
    
    Types: 
        <http://purl.org/dc/dcmitype/Collection>
    
    
Individual: <urn:uuid:9d536abb-5eb3-4ae7-9e1e-cebdea9a36b4>

    Annotations: 
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0>,
        oa:hasSelector <urn:uuid:b849f98a-a8dc-4acd-8f4f-ea0b45c7fa5e>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/indicationsAndUsage>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: spl:pharmgx-spl-annotation-set-9

    Annotations: 
        oa:onResource <file:///home/rdb20/Downloads/d2rq-0.8.1/linkedSPLs-dump.nt#structuredProductLabelMetadata/16bda7b5-a5a5-4478-9df3-beb396bd677f>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-65>,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-40>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-9>
    
    Types: 
        <http://purl.org/dc/dcmitype/Collection>
    
    
Individual: <urn:uuid:41c75d04-9d7a-4f72-8cfb-3d7fcbd75069>

    Annotations: 
        oa:exact "Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir. Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of hypersensitivity reaction. Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir. HLA-B*5701-negative patients may develop a suspected hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients. Regardless of HLA-B*5701 status, permanently discontinue EPZICOM if hypersensitivity cannot be ruled out, even when other diagnoses are possible. Following a hypersensitivity reaction to abacavir, NEVER restart EPZICOM or any other abacavir-containing product because more severe symptoms can occur within hours and may include life-threatening hypotension and death.",
        oa:postfix " Reintroduction of EPZICOM or any other abacavir-c",
        oa:prefix "soon as a hypersensitivity reaction is suspected. "
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: spl:pharmgx-spl-annotation-set-8

    Annotations: 
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-38>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-63>,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-32>,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-57>,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-58>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:onResource <file:///home/rdb20/Downloads/d2rq-0.8.1/linkedSPLs-dump.nt#structuredProductLabelMetadata/128846a7-18c6-4bc4-b3a0-9aeed0e8b986>,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-8>
    
    Types: 
        <http://purl.org/dc/dcmitype/Collection>
    
    
Individual: <urn:uuid:3764d067-0b68-46ff-bdb9-253672e163a6>

    Annotations: 
        oa:postfix ". Bleeding is more likely to occur during the star",
        oa:prefix "etion. Considerations for Increased Bleeding Risk ",
        oa:exact "Warfarin sodium is a narrow therapeutic range (index) drug, and additional caution should be observed when warfarin sodium is administered to certain patients. Reported risk factors for bleeding include high intensity of anticoagulation (INR >4.0), agehighly variable INRs, history of gastrointestinal bleeding, hypertension, cerebrovascular disease, serious heart disease, anemia, malignancy, trauma, renal insufficiency, concomitant drugs (seePRECAUTIONS) and long duration of warfarin therapy. Identification of risk factors for bleeding and certain genetic variations in CYP2C9 and VKORC1 in a patient may increase the need for more frequent INR monitoring and the use of lower warfarin doses (see CLINICAL PHARMACOLOGY:PharmacokineticsMetabolismandDOSAGE AND ADMINISTRATION)"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: spl:pharmgx-spl-annotation-body-11

    Annotations: 
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "CLOPIDOGREL",
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2C19",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Clopidogrel>,
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2C19>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        spl:PharmacodynamicImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00758>
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-12

    Annotations: 
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "CLOPIDOGREL",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Clopidogrel>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2C19",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2C19>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>,
        spl:PharmacodynamicImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00758>
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-13

    Annotations: 
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "CLOPIDOGREL",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Clopidogrel>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2C19",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2C19>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        spl:PharmacodynamicImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00758>
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: <urn:uuid:94495cce-be72-407a-907d-173c224e211a>

    Annotations: 
        oa:prefix "ocytic anemia and/or bleeding have been reported. ",
        oa:exact "TPMT genotyping or phenotyping can help identify patients with low or absent TPMT activity (homozygous for non-functional alleles) who are at increased risk for severe, life-threatening myelosuppression from azathioprine tablets (see CLINICAL PHARMACOLOGY, WARNINGS and PRECAUTIONS: Laboratory Tests). Death associated with pancytopenia has been reported in patients with absent TPMT activity receiving azathioprine.6, 20",
        oa:postfix " Gastrointestinal Nausea and vomiting may occur wi"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:6d486688-5c78-414d-a429-2ad69ddabac2>

    Annotations: 
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=040d010a-b1b2-4db7-905d-8aa7f1bab0cd>,
        oa:hasSelector <urn:uuid:ce93ba8e-ecca-4761-af1c-e91d82dd6f53>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/adverseReactions>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: spl:pharmgx-spl-annotation-item-10

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasTarget <urn:uuid:ed8a1ac2-215c-45a1-a943-0a6eba67d939>,
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-10>
    
    Types: 
        oa:Annotation
    
    
Individual: <urn:uuid:951e98d8-3093-462f-a9bd-88c34d7b6969>

    Annotations: 
        oa:postfix " If symptoms consistent with hypersensitivity are ",
        oa:prefix "e is recommended prior to reinitiation of ZIAGEN. ",
        oa:exact "If hypersensitivity cannot be ruled out, DO NOT reintroduce ZIAGEN or any other abacavir-containing product. Even in the absence of the HLA-B*5701 allele, it is important to permanently discontinue abacavir and not rechallenge with abacavir if a hypersensitivity reaction cannot be ruled out on clinical grounds, due to the potential for a severe or even fatal reaction."
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:2e806231-c922-4f27-819c-7295e463e529>

    Annotations: 
        oa:prefix "nd the 2-oxo-clopidogrel intermediate metabolite. ",
        oa:postfix "ype.   A crossover study in 40 healthy subjects, ",
        oa:exact "Clopidogrel active metabolite pharmacokinetics and antiplatelet effects, as measured by ex vivo platelet aggregation assays, differ according to CYP2C19 genotype. Genetic variants of other CYP450 enzymes may also affect the formation of clopidogrel’s active metabolite. The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and *3 alleles are nonfunctional. CYP2C19*2 and *3 account for the majority of reduced function alleles in white (85%) and Asian (99%) poor metabolizers. Other alleles associated with absent or reduced metabolism are less frequent, and include, but are not limited to, CYP2C19*4, *5, *6, *7, and *8. A patient with poor metabolizer status will possess two loss-of-function alleles as defined above. Published frequencies for poor CYP2C19 metabolizer genotypes are approximately 2% for whites, 4% for blacks and 14% for Chinese. Tests are available to determine a patient’s CYP2C19 genot"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: spl:pharmgx-spl-annotation-set-10

    Annotations: 
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-60>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:onResource <file:///home/rdb20/Downloads/d2rq-0.8.1/linkedSPLs-dump.nt#structuredProductLabelMetadata/3d021d9b-c0b8-41a3-a99b-37f50d2a20ae>,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-33>,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-41>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-10>
    
    Types: 
        <http://purl.org/dc/dcmitype/Collection>
    
    
Individual: spl:pharmgx-spl-annotation-body-14

    Annotations: 
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "CLOPIDOGREL",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Clopidogrel>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2C19",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2C19>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>,
        spl:PharmacodynamicImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00758>
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-item-11

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasTarget <urn:uuid:8e841220-a6f0-4e85-a163-91722d4fc357>,
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-11>
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-body-15

    Annotations: 
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2D6",
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "CODEINE",
        spl:PharmacodynamicImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased>,
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2D6>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00318>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-16

    Annotations: 
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2D6",
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "CODEINE",
        spl:PharmacodynamicImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased>,
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2D6>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00318>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-17

    Annotations: 
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00675>,
        spl:PharmacodynamicImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "ER_receptor",
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "TAMOXIFEN"
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: <urn:uuid:6ab3e2fa-7238-46ba-8efe-4abe862af5da>

    Annotations: 
        oa:exact "When therapy with ZIAGEN has been discontinued for reasons other than symptoms of a hypersensitivity reaction, and if reinitiation of ZIAGEN or any other abacavir-containing product is under consideration, carefully evaluate the reason for discontinuation of ZIAGEN to ensure that the patient did not have symptoms of a hypersensitivity reaction. If the patient is of unknown HLA-B*5701 status, screening for the allele is recommended prior to reinitiation of ZIAGEN. If hypersensitivity cannot be ruled out, DO NOT reintroduce ZIAGEN or any other abacavir-containing product. Even in the absence of the HLA-B*5701 allele, it is important to permanently discontinue abacavir and not rechallenge with abacavir if a hypersensitivity reaction cannot be ruled out on clinical grounds, due to the potential for a severe or even fatal reaction.",
        oa:postfix " If symptoms consistent with hypersensitivity are ",
        oa:prefix "y include life-threatening hypotension and death. "
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: spl:pharmgx-spl-annotation-body-18

    Annotations: 
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00675>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "ER_receptor",
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        spl:PharmacodynamicImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "TAMOXIFEN"
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-21

    Annotations: 
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2C9>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Warfarin>,
        spl:PharmacodynamicImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00682>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "WARFARIN",
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2C9"
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-item-37

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-37>,
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasTarget <urn:uuid:384a4f55-72b6-46e4-9079-1bfffc353193>
    
    Types: 
        oa:Annotation
    
    
Individual: <urn:uuid:44226e6f-2f63-4f3a-984e-43d302442b81>

    Annotations: 
        oa:postfix "S] 8.4 Pediatric Use The safety and effectiveness ",
        oa:prefix "id-induced respiratory depression in the neonate. ",
        oa:exact "8.3 Nursing Mothers Codeine is secreted into human milk. In women with normal codeine metabolism (normal CYP2D6 activity), the amount of codeine secreted into human milk is low and dose-dependent. However, some women are ultra-rapid metabolizers of codeine. These women achieve higher-than-expected serum levels of codeine’s active metabolite, morphine, leading to higher-than-expected levels of morphine in breast milk and potentially dangerously high serum morphine levels in their breastfed infants. Therefore, maternal use of codeine can potentially lead to serious adverse reactions, including death, in nursing infants. The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese and Japanese, 0.5 to 1% in Hispanics, 1 to 10% in Caucasians, 3% in African Americans, and 16 to 28% in North Africans, Ethiopians, and Arabs. Data are not available for other ethnic groups. The risk of infant exposure to codeine and morphine through breast milk should be weighed against the benefits of breastfeeding for both the mother and the baby. Caution should be exercised when codeine is administered to a nursing woman. If a codeine containing product is selected, the lowest dose should be prescribed for the shortest period of time to achieve the desired clinical effect. Mothers using codeine should be informed about when to seek immediate medical care and how to identify the signs and symptoms of neonatal toxicity, such as drowsiness or sedation, difficulty breastfeeding, breathing difficulties, and decreased tone, in their baby. Nursing mothers who are ultra-rapid metabolizers may also experience overdose symptoms such as extreme sleepiness, confusion, or shallow breathing. Prescribers should closely monitor mother-infant pairs and notify treating pediatricians about the use of codeine during breastfeeding. [see 5 WARNINGS AND PRECAUTION"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: spl:pharmgx-spl-annotation-body-20

    Annotations: 
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2C9>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>,
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Warfarin>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00682>,
        spl:PharmacodynamicImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "WARFARIN",
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2C9"
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-item-36

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:hasTarget <urn:uuid:0c213c3e-0047-4bc4-99fd-5e73583a8888>,
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-36>,
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-35

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-35>,
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasTarget <urn:uuid:df428acd-76dc-415c-87ed-f4d966f3ff2b>
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-34

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:hasTarget <urn:uuid:8da4db8d-c421-40a1-9802-57b8d2163229>,
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-34>
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-39

    Annotations: 
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-39>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasTarget <urn:uuid:5b509503-2da7-4121-bffb-4d42e439bffa>
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-38

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-38>,
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:hasTarget <urn:uuid:b04672aa-311c-4c9e-b592-d2eb55481d46>,
        oa:annotatedAt "2013-03-13"^^xsd:date
    
    Types: 
        oa:Annotation
    
    
Individual: <urn:uuid:56ee2f99-5a66-4839-9a21-0db01be54fd5>

    Annotations: 
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/precautions>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=407a372d-4448-4d53-afd4-eb0e74bbc336>,
        oa:hasSelector <urn:uuid:b9712f8a-87a2-4080-9d33-95b3a0e50f05>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:e8e1d299-f0b2-4e29-aa27-8c33404b1e9c>

    Annotations: 
        oa:hasSelector <urn:uuid:1ac4c4a2-d387-4e86-8cf1-0a1ed7c99839>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/useInSpecificPopulations>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa3ed180-298a-4f9d-9d05-15182d7218bf>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:b75f0016-423e-4d4b-8dbb-99223ce8381a>

    Annotations: 
        oa:hasSelector <urn:uuid:f2470e11-f784-402d-83a5-3597a9ce905a>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c3248d43-3dd6-4ca9-afca-528c7abe0fce>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinicalPharmacology>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:8e841220-a6f0-4e85-a163-91722d4fc357>

    Annotations: 
        oa:hasSelector <urn:uuid:8e843bf8-61bb-4505-8f33-e4aa43a46576>,
        oa:hasSelector <urn:uuid:a47dc7c5-6700-4244-96f5-1c6f653aa2f8>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c3248d43-3dd6-4ca9-afca-528c7abe0fce>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinicalPharmacology>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: spl:pharmgx-spl-annotation-body-28

    Annotations: 
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB01048>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>,
        spl:TestRecommendation <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "ABACAVIR",
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "HLA-B*5701"
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-item-40

    Annotations: 
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-40>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasTarget <urn:uuid:36193591-e36c-47b2-8364-bafedda76822>
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-body-29

    Annotations: 
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB01048>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        spl:TestRecommendation <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "ABACAVIR",
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "HLA-B*5701"
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-26

    Annotations: 
        spl:PharmacodynamicImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "VKORC1",
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>,
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Warfarin>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00682>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "WARFARIN",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#VKORC1>
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: <urn:uuid:011d66ae-2e94-4e6f-a4b1-1612179546bd>

    Annotations: 
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa3ed180-298a-4f9d-9d05-15182d7218bf>,
        oa:hasSelector <urn:uuid:a1083ebf-25a2-4f79-8868-79f4c9727827>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/warningsAndPrecautions>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: spl:pharmgx-spl-annotation-body-27

    Annotations: 
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "VKORC1",
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        spl:PharmacodynamicImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response>,
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Warfarin>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00682>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "WARFARIN",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#VKORC1>
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: <urn:uuid:ed8a1ac2-215c-45a1-a943-0a6eba67d939>

    Annotations: 
        oa:hasSelector <urn:uuid:dd2137a2-1c56-4a72-a417-e1b43198ac08>,
        oa:hasSelector <urn:uuid:dafccef8-8cf3-4df3-ab5a-b3631d7a9d27>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/boxedWarning>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d021d9b-c0b8-41a3-a99b-37f50d2a20ae>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: spl:pharmgx-spl-annotation-body-24

    Annotations: 
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "VKORC1",
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>,
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Warfarin>,
        spl:PharmacodynamicImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00682>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#VKORC1>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "WARFARIN"
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-item-43

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-43>,
        oa:hasTarget <urn:uuid:1f176514-f7dc-4f46-b190-5f05455d288c>,
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date
    
    Types: 
        oa:Annotation
    
    
Individual: <urn:uuid:7cbd0eb7-df9e-4d9c-93e1-481a1c00979b>

    Annotations: 
        oa:exact "CYP2C9, a polymorphic enzyme, is likely to be the principal form of human liver CYP450 that modulates the in vivo anticoagulant activity of warfarin. Patients with one or more variant CYP2C9 alleles have decreased S-warfarin clearance",
        oa:prefix "in include CYP2C9, 2C19, 2C8, 2C18, 1A2, and 3A4. ",
        oa:postfix " Excretion The terminal half-life of warfarin afte"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: spl:pharmgx-spl-annotation-body-25

    Annotations: 
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "VKORC1",
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>,
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Warfarin>,
        spl:PharmacodynamicImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00682>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "WARFARIN",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#VKORC1>
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-item-44

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-44>,
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasTarget <urn:uuid:ca086c56-a872-4a0c-b16e-06d067518318>
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-body-22

    Annotations: 
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2C9>,
        spl:PharmacodynamicImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>,
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Warfarin>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00682>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "WARFARIN",
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2C9"
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-item-41

    Annotations: 
        oa:hasTarget <urn:uuid:dd236914-a400-409f-88b0-0d372e66de1e>,
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-41>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date
    
    Types: 
        oa:Annotation
    
    
Individual: <urn:uuid:036d5eb3-2c0b-4572-9df2-0b08bc69c1b4>

    Annotations: 
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f1139e7f-2db9-4961-9da3-9b7f2088736f>,
        oa:hasSelector <urn:uuid:183fae1a-62c5-48b1-8a74-24c9bac2a7cb>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/boxedWarning>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: spl:pharmgx-spl-annotation-body-23

    Annotations: 
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2C9>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        spl:PharmacodynamicImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response>,
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Warfarin>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00682>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "WARFARIN",
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2C9"
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-item-42

    Annotations: 
        oa:hasTarget <urn:uuid:b28f4365-d26c-4930-b3b0-ba0cf014fb09>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-42>,
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date
    
    Types: 
        oa:Annotation
    
    
Individual: <urn:uuid:1f176514-f7dc-4f46-b190-5f05455d288c>

    Annotations: 
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03bec9ad-cd22-44d3-9b82-2796157de1d1>,
        oa:hasSelector <urn:uuid:af81e7c7-89e3-48f5-81f7-a4f807625195>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/dosageAndAdministration>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: spl:pharmgx-spl-annotation-item-24

    Annotations: 
        oa:hasTarget <urn:uuid:e9193721-82c5-49eb-82e8-f08456eb60c0>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-24>,
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date
    
    Types: 
        oa:Annotation
    
    
Individual: <urn:uuid:a8f32294-e016-46d0-877f-7683d960d5c2>

    Annotations: 
        oa:exact "Ultra-Rapid Metabolizers of Codeine Some individuals may be ultra-rapid metabolizers due to a specific CYP2D6*2x2 genotype. These individuals convert codeine into its active metabolite, morphine, more rapidly and completely than other people. This rapid conversion results in higher than expected serum morphine levels. Even at labeled dosage regimens, individuals who are ultra-rapid metabolizers may experience overdose symptoms such as extreme sleepiness, confusion, or shallow breathing. The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese and Japanese, 0.5 to 1% in Hispanics, 1 to 10% in Caucasians, 3% in African Americans, and 16 to 28% in North Africans, Ethiopians, and Arabs. Data are not available for other ethnic groups. When physicians prescribe codeine-containing drugs, they should choose the lowest effective dose for the shortest period of time and inform their patients about these risks and the signs of morphine overdose. [see 8 USE IN SPECIFIC POPULATIONS]",
        oa:prefix "aggravate seizures in some clinical settings. 5.9 ",
        oa:postfix " 5.10 Driving and Operating Machinery Patients sho"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: spl:pharmgx-spl-annotation-body-30

    Annotations: 
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Azathioprine>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "AZATHIOPRINE",
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        spl:TestRecommendation <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-available>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00993>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "TPMT"
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-item-23

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-23>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasTarget <urn:uuid:eee3489f-0618-47c1-8385-e4277010dced>
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-26

    Annotations: 
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-26>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:hasTarget <urn:uuid:1b830b10-8ac0-447d-b91a-2b76337ff76c>,
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-body-32

    Annotations: 
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Azathioprine>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "AZATHIOPRINE",
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00993>,
        spl:TestRecommendation <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-available>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "TPMT"
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-31

    Annotations: 
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Azathioprine>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "AZATHIOPRINE",
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00993>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        spl:TestRecommendation <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-available>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "TPMT"
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-item-25

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-25>,
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasTarget <urn:uuid:06d9293e-715b-49c2-9f32-7a561c8b8db7>
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-28

    Annotations: 
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-28>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasTarget <urn:uuid:3fa7a6d2-ea52-4b80-ab37-c1132bd97ccc>
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-27

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-27>,
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasTarget <urn:uuid:601b54f5-c4c8-4dca-8dec-c6f57fe46d1f>
    
    Types: 
        oa:Annotation
    
    
Individual: <urn:uuid:c3ebeb24-acd7-492f-9015-92359262319b>

    Annotations: 
        oa:exact "Azathioprine is metabolized to 6-mercaptopurine (6-MP). Both compounds are rapidly eliminated from blood and are oxidized or methylated in erythrocytes and liver; no azathioprine or mercaptopurine is detectable in urine after 8 hours. Activation of 6-mercaptopurine occurs via hypoxanthine-guanine phosphoribosyltransferase (HGPRT) and a series of multi-enzymatic processes involving kinases to form 6-thioguanine nucleotides (6TGNs) as major metabolites (See Metabolism Scheme in Figure 1). The cytotoxicity of azathioprine is due, in part, to the incorporation of 6-TGN into DNA. 6-MP undergoes two major inactivation routes (Figure 1). One is thiol methylation, which is catalyzed by the enzyme thiopurine S-methyltransferase (TPMT), to form the inactive metabolite methyl-6-MP (6-MeMP). TPMT activity is controlled by a genetic polymorphism. 1,2,3 For Caucasians and African Americans, approximately 10% of the population inherit one non-functional TPMT allele (heterozygous) conferring intermediate TPMT activity, and 0.3% inherit two TPMT non-functional alleles (homozygous) for low or absent TPMT activity. Non-functional alleles are less common in Asians. TPMT activity correlates inversely with 6TGN levels in erythrocytes and presumably other hematopoietic tissues, since these cells have negligible xanthine oxidase (involved in the other inactivation pathway) activities, leaving TPMT methylation as the only inactivation pathway. Patients with intermediate TPMT activity may be at increased risk of myelotoxicity if receiving conventional doses of azathioprine. Patients with low or absent TPMT activity are at an increased risk of developing severe, life-threatening myelotoxicity if receiving conventional doses of azathioprine.4-9 TPMT genotyping or phenotyping (red blood cell TPMT activity) can help identify patients who are at an increased risk for developing azathioprine toxicity.2, 3, 7, 8, 9 Accurate phenotyping (red blood cell TPMT activity) results are not possible in patients who have received recent blood transfusions. (See WARNINGS, PRECAUTIONS: Drug Interactions, PRECAUTIONS: Laboratory Tests and ADVERSE REACTIONS sections)",
        oa:postfix ". Figure 1. Metabolism pathway of azathioprine : c",
        oa:prefix " and are partially dialyzable. (See OVERDOSAGE ). "
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: spl:pharmgx-spl-annotation-item-29

    Annotations: 
        oa:hasTarget <urn:uuid:7773a273-d4c8-4dec-ba9e-597929b491a7>,
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-29>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date
    
    Types: 
        oa:Annotation
    
    
Individual: <urn:uuid:3dc3d39d-3e84-4665-897a-12cd29b9d1bf>

    Annotations: 
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7500c65e-9680-4719-b426-90a7162352c9>,
        oa:hasSelector <urn:uuid:c3ebeb24-acd7-492f-9015-92359262319b>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinicalPharmacology>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:9cf2b3b9-3dab-4b9e-90a4-15df8790504b>

    Annotations: 
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/precautions>,
        oa:hasSelector <urn:uuid:336086ef-054e-4242-978c-cc0a89233278>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:36193591-e36c-47b2-8364-bafedda76822>

    Annotations: 
        oa:hasSelector <urn:uuid:89e91a6c-01c4-49f8-947c-3f7578772c70>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=16bda7b5-a5a5-4478-9df3-beb396bd677f>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/warnings>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:6eb1c899-5526-4df7-be46-1e8bf6bc7b27>

    Annotations: 
        oa:prefix "settings. 5.9 Ultra-Rapid Metabolizers of Codeine ",
        oa:postfix " 5.10 Driving and Operating Machinery Patients sho",
        oa:exact "Some individuals may be ultra-rapid metabolizers due to a specific CYP2D6*2x2 genotype. These individuals convert codeine into its active metabolite, morphine, more rapidly and completely than other people. This rapid conversion results in higher than expected serum morphine levels. Even at labeled dosage regimens, individuals who are ultra-rapid metabolizers may experience overdose symptoms such as extreme sleepiness, confusion, or shallow breathing. The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese and Japanese, 0.5 to 1% in Hispanics, 1 to 10% in Caucasians, 3% in African Americans, and 16 to 28% in North Africans, Ethiopians, and Arabs. Data are not available for other ethnic groups. When physicians prescribe codeine-containing drugs, they should choose the lowest effective dose for the shortest period of time and inform their patients about these risks and the signs of morphine overdose. [see 8 USE IN SPECIFIC POPULATIONS]"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:2d1a6a6a-8aae-493c-b19e-1a1641fa2b41>

    Annotations: 
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/precautions>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=87315917-3e54-44e6-bb64-2f722501c11b>,
        oa:hasSelector <urn:uuid:18656609-c71d-46f6-b2a6-22bbfebbc4e2>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:dd2137a2-1c56-4a72-a417-e1b43198ac08>

    Annotations: 
        oa:exact "Clopidogrel  bisulfate at recommended doses forms less of that metabolite and has a smaller effect on platelet function in patients who are CYP2C19 poor metabolizers.  Poor metabolizers with acute coronary syndrome or undergoing percutaneous coronary intervention treated with clopidogrel bisulfate at recommended doses exhibit higher cardiovascular event rates than do patients with normal CYP2C19 function. Tests are available to identify a patient's CYP2C19 genotype; these tests can be used as an aid in determining therapeutic strategy [see Clinical Pharmacology (12.5)]. Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers [see Dosage and Administration",
        oa:postfix " (2.3)]. WARNING: DIMINISHED EFFECTIVENESS IN POOR",
        oa:prefix "lly CYP2C19 [see Warnings and Precautions (5.1)]. "
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:36d9a9a3-d77b-443f-98d4-cc437ad35826>

    Annotations: 
        oa:hasSelector <urn:uuid:50dcc8f4-1991-4b87-973d-d143722f3c9d>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c95f0b0d-77ef-e753-be04-2228139df2d3>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/dosageAndAdministration>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:d73cbc6e-3847-4fd3-837b-ee3f14abfc85>

    Annotations: 
        oa:hasSelector <urn:uuid:7cbd0eb7-df9e-4d9c-93e1-481a1c00979b>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ab047628-67d0-4a64-8d77-36b054969b44>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinicalPharmacology>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: spl:pharmgx-spl-annotation-body-37

    Annotations: 
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Azathioprine>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "AZATHIOPRINE",
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00993>,
        spl:PharmacokineticImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "TPMT"
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-38

    Annotations: 
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "AZATHIOPRINE",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Azathioprine>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00993>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        spl:PharmacokineticImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "TPMT"
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-39

    Annotations: 
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Azathioprine>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "AZATHIOPRINE",
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00993>,
        spl:PharmacokineticImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "TPMT"
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-33

    Annotations: 
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "CLOPIDOGREL",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Clopidogrel>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2C19",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2C19>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>,
        spl:TestRecommendation <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-available>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00758>
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-item-30

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:hasTarget <urn:uuid:4a50732e-1578-4298-9c62-9f42ed2550c9>,
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-30>
    
    Types: 
        oa:Annotation
    
    
Individual: <urn:uuid:97171eb7-e0c8-451d-ae4d-89a7b8ca8c86>

    Annotations: 
        oa:exact "Table 1 displays three ranges of expected maintenance warfarin sodium doses observed in subgroups of patients having different combinations of CYP2C9 and VKORC1 gene variants [see Clinical Pharmacology (12.5)]. If the patient's CYP2C9 and/or VKORC1 genotype are known, consider these ranges in choosing the initial dose. Patients with CYP2C9 *1/*3, *2/*2, *2/*3, and *3/*3 may require more prolonged time (>2 to 4 weeks) to achieve maximum INR effect for a given dosage regimen than patients without these CYP variants.",
        oa:postfix " 2.4 Monitoring to Achieve Optimal Anticoagulation",
        oa:prefix "ng Recommendations with Consideration of Genotype "
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: spl:pharmgx-spl-annotation-item-31

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:hasTarget <urn:uuid:5601264a-45a1-43ff-9256-0702d199c5df>,
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-31>,
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-body-34

    Annotations: 
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "CLOPIDOGREL",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Clopidogrel>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2C19",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2C19>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#TestRecommendation>,
        spl:TestRecommendation <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-available>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00758>
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-35

    Annotations: 
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2D6",
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>,
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2D6>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB01238>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        spl:PharmacokineticImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "ARIPIPRAZOLE"
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-item-32

    Annotations: 
        oa:hasTarget <urn:uuid:b647d7f6-f1e3-443c-bbec-6a336ab2b87d>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-32>
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-33

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:hasTarget <urn:uuid:20ee62b5-5db5-4498-ac4f-6930cbf79cd3>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-33>
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-body-36

    Annotations: 
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "AZATHIOPRINE",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Azathioprine>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00993>,
        spl:PharmacokineticImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "TPMT"
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: <urn:uuid:ac6f461f-9c5c-4bca-98ef-55b7c54b667c>

    Annotations: 
        oa:exact "In TRITON-TIMI 38 and the majority of the cohort studies, the combined group of patients with either intermediate or poor metabolizer status had a higher rate of cardiovascular events (death, myocardial infarction, and stroke) or stent thrombosis compared to extensive metabolizers. In CHARISMA and one cohort study, the increased event rate was observed only in poor metabolizers.",
        oa:postfix "",
        oa:prefix "n=1477), and in several published cohort studies. "
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:26153aed-9c18-40a6-9f56-1e98c6236d18>

    Annotations: 
        oa:hasSelector <urn:uuid:36edf6a8-3df6-4e0b-af82-7eaf73a6128c>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa3ed180-298a-4f9d-9d05-15182d7218bf>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/warningsAndPrecautions>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:03bd6e72-f790-49a2-ac80-79350e03f241>

    Annotations: 
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ab047628-67d0-4a64-8d77-36b054969b44>,
        oa:hasSelector <urn:uuid:97171eb7-e0c8-451d-ae4d-89a7b8ca8c86>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/dosageAndAdministration>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:0ce7b630-0e6d-43fa-8044-dfb33908404d>

    Annotations: 
        oa:prefix "djusted to achieve a favorable clinical response. ",
        oa:postfix " Dosage adjustment for patients taking potential C",
        oa:exact "Dosing recommendation in patients who are classified as CYP2D6 poor metabolizers (PM): The aripiprazole dose in PM patients should initially be reduced to one-half (50%) of the usual dose and then adjusted to achieve a favorable clinical response. The dose of aripiprazole for PM patients who are administered a strong CYP3A4 inhibitor should be reduced to one-quarter (25%) of the usual dose [see CLINICAL PHARMACOLOGY (12.3)]."
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:7f73d2b8-86f0-4431-80c5-944ea4c1d7ea>

    Annotations: 
        oa:postfix "S] 8.4 Pediatric Use The safety and effectiveness ",
        oa:prefix "id-induced respiratory depression in the neonate. ",
        oa:exact "8.3 Nursing Mothers Codeine is secreted into human milk. In women with normal codeine metabolism (normal CYP2D6 activity), the amount of codeine secreted into human milk is low and dose-dependent. However, some women are ultra-rapid metabolizers of codeine. These women achieve higher-than-expected serum levels of codeine’s active metabolite, morphine, leading to higher-than-expected levels of morphine in breast milk and potentially dangerously high serum morphine levels in their breastfed infants. Therefore, maternal use of codeine can potentially lead to serious adverse reactions, including death, in nursing infants. The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese and Japanese, 0.5 to 1% in Hispanics, 1 to 10% in Caucasians, 3% in African Americans, and 16 to 28% in North Africans, Ethiopians, and Arabs. Data are not available for other ethnic groups. The risk of infant exposure to codeine and morphine through breast milk should be weighed against the benefits of breastfeeding for both the mother and the baby. Caution should be exercised when codeine is administered to a nursing woman. If a codeine containing product is selected, the lowest dose should be prescribed for the shortest period of time to achieve the desired clinical effect. Mothers using codeine should be informed about when to seek immediate medical care and how to identify the signs and symptoms of neonatal toxicity, such as drowsiness or sedation, difficulty breastfeeding, breathing difficulties, and decreased tone, in their baby. Nursing mothers who are ultra-rapid metabolizers may also experience overdose symptoms such as extreme sleepiness, confusion, or shallow breathing. Prescribers should closely monitor mother-infant pairs and notify treating pediatricians about the use of codeine during breastfeeding. [see 5 WARNINGS AND PRECAUTION"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:464bfaec-724a-4e93-8ce9-d67bff139e75>

    Annotations: 
        oa:exact "Clopidogrel  bisulfate at recommended doses forms less of that metabolite and has a smaller effect on platelet function in patients who are CYP2C19 poor metabolizers.  Poor metabolizers with acute coronary syndrome or undergoing percutaneous coronary intervention treated with clopidogrel bisulfate at recommended doses exhibit higher cardiovascular event rates than do patients with normal CYP2C19 function. Tests are available to identify a patient's CYP2C19 genotype; these tests can be used as an aid in determining therapeutic strategy [see Clinical Pharmacology (12.5)]. Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers [see Dosage and Administration",
        oa:postfix " (2.3)]. WARNING: DIMINISHED EFFECTIVENESS IN POOR",
        oa:prefix "lly CYP2C19 [see Warnings and Precautions (5.1)]. "
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:b8ceec74-9cde-4e04-8472-210c94991453>

    Annotations: 
        oa:exact "Screening for carriage of the HLA -B*5701 allele is recommended prior to initiating treatment with abacavir. Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir. For HLA-B*5701-positive patients, initiating or reinitiating treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances where potential benefit outweighs the risk.",
        oa:prefix "f patients who do not have the HLA-B*5701 allele. ",
        oa:postfix " Skin patch testing is used as a research tool and"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:06d9293e-715b-49c2-9f32-7a561c8b8db7>

    Annotations: 
        oa:hasSelector <urn:uuid:1202299d-581a-4ff6-ac7a-494368c7e30a>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/dosageAndAdministration>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c95f0b0d-77ef-e753-be04-2228139df2d3>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:3fa7a6d2-ea52-4b80-ab37-c1132bd97ccc>

    Annotations: 
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f1139e7f-2db9-4961-9da3-9b7f2088736f>,
        oa:hasSelector <urn:uuid:41c75d04-9d7a-4f72-8cfb-3d7fcbd75069>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/boxedWarning>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:b04672aa-311c-4c9e-b592-d2eb55481d46>

    Annotations: 
        oa:hasSelector <urn:uuid:089ec7d8-3734-4e40-9ebb-f69d6f34cc1e>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=128846a7-18c6-4bc4-b3a0-9aeed0e8b986>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/dosageAndAdministration>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:9bf90051-9a72-43ee-bca7-c28bdf625a80>

    Annotations: 
        oa:hasSelector <urn:uuid:7f73d2b8-86f0-4431-80c5-944ea4c1d7ea>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/useInSpecificPopulations>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa3ed180-298a-4f9d-9d05-15182d7218bf>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:5b509503-2da7-4121-bffb-4d42e439bffa>

    Annotations: 
        oa:hasSelector <urn:uuid:e63291ed-b7d7-4025-b329-9ecc563cd5ac>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/drugInteractions>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=49212741-389f-4112-94a9-d14ea2115825>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:e5dfedf3-0240-4fc5-9ca1-6489d2723c34>

    Annotations: 
        oa:hasSelector <urn:uuid:0ce7b630-0e6d-43fa-8044-dfb33908404d>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d8275c2d-f42d-4f32-aa9f-03a202c8e99f>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/dosageAndAdministration>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:72e5d6f1-23a1-45b7-bcd9-dfeb7c4d7541>

    Annotations: 
        oa:prefix "tabolizers [see Dosage and Administration (2.3)]. ",
        oa:exact "WARNING: DIMINISHED EFFECTIVENESS IN POOR METABOLIZERS   See full prescribing information for complete boxed warning.   Effectiveness of clopidogrel bisulfate depends on activation to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19. (5.1) Poor metabolizers treated with clopidogrel bisulfate at recommended doses exhibit higher cardiovascular event rates following acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) than patients with normal CYP2C19 function. (12.5) Tests are available to identify a patient's CYP2C19 genotype and can be used as an aid in determining therapeutic strategy. (12.5) Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers. (2.3, 5.",
        oa:postfix "1)"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:cf8f868b-9b69-4de9-a05a-5378a1ad99ef>

    Annotations: 
        oa:hasSelector <urn:uuid:c5ef61eb-54db-41eb-85d0-c0404c112816>,
        oa:hasSelector <urn:uuid:936119ff-10f0-4603-8149-ae256f1fce69>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c3248d43-3dd6-4ca9-afca-528c7abe0fce>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinicalPharmacology>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:5db4f1be-50b0-4813-8488-2e6078a155c0>

    Annotations: 
        oa:prefix "DOSAGE AND ADMINISTRATION ",
        oa:postfix " Renal Homotransplantation The dose of azathioprin",
        oa:exact "TPMT TESTING CANNOT SUBSTITUTE FOR COMPLETE BLOOD COUNT (CBC) MONITORING IN PATIENTS RECEIVING AZATHIOPRINE TABLETS. TPMT genotyping or phenotyping can be used to identify patients with absent or reduced TPMT activity. Patients with low or absent TPMT activity are at an increased risk of developing severe, life-threatening myelotoxicity from azathioprine tablets if conventional doses are given. Physicians may consider alternative therapies for patients who have low or absent TPMT activity (homozygous for non-functional alleles). Azathioprine tablets should be administered with caution to patients having one non-functional allele (heterozygous) who are at risk for reduced TPMT activity that may lead to toxicity if conventional doses are given. Dosage reduction is recommended in patients with reduced TPMT activity. Early drug discontinuation may be considered in patients with abnormal CBC results that do not respond to dose reduction."
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:52efa0ca-083f-4103-95fe-bc27a2421d0e>

    Annotations: 
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ab047628-67d0-4a64-8d77-36b054969b44>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinicalPharmacology>,
        oa:hasSelector <urn:uuid:0b1392ad-f755-4c05-8f1c-7fd804abb04b>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:bee03e84-6eec-413a-86f9-8c2e14d60cf8>

    Annotations: 
        oa:hasSelector <urn:uuid:44226e6f-2f63-4f3a-984e-43d302442b81>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/useInSpecificPopulations>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa3ed180-298a-4f9d-9d05-15182d7218bf>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: spl:pharmgx-spl-annotation-set-19

    Annotations: 
        oa:onResource <file:///home/rdb20/Downloads/d2rq-0.8.1/linkedSPLs-dump.nt#structuredProductLabelMetadata/49212741-389f-4112-94a9-d14ea2115825>,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-39>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-64>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-59>
    
    Types: 
        <http://purl.org/dc/dcmitype/Collection>
    
    
Individual: <urn:uuid:a47dc7c5-6700-4244-96f5-1c6f653aa2f8>

    Annotations: 
        oa:exact "CYP2C19 is involved in the formation of both the active metabolite and the 2-oxo-clopidogrel intermediate metabolite. Clopidogrel active metabolite pharmacokinetics and antiplatelet effects, as measured by ex vivo platelet aggregation assays, differ according to CYP2C19 genotype. Genetic variants of other CYP450 enzymes may also affect the formation of clopidogrel’s active metabolite. The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and *3 alleles are nonfunctional. CYP2C19*2 and *3 account for the majority of reduced function alleles in white (85%) and Asian (99%) poor metabolizers. Other alleles associated with absent or reduced metabolism are less frequent, and include, but are not limited to, CYP2C19*4, *5, *6, *7, and *8. A patient with poor metabolizer status will possess two loss-of-function alleles as defined above. Published frequencies for poor CYP2C19 metabolizer genotypes are approximately 2% for whites, 4% for blacks and 14% for Chinese. Tests are available to determine a patient’s CYP2C19 genotype.   A crossover study in 40 healthy subjects, 10 each in the four CYP2C19 metabolizer groups, evaluated pharmacokinetic and antiplatelet responses using 300 mg followed by 75 mg per day and 600 mg followed by 150 mg per day, each for a total of 5 days. Decreased active metabolite exposure and diminished inhibition of platelet aggregation were observed in the poor metabolizers as compared to the other groups. When poor metabolizers received the 600 mg/150 mg regimen, active metabolite exposure and antiplatelet response were greater than with the 300 mg/75 mg regimen (see Table 3). An appropriate dose regimen for this patient population has not been established in clinical outcome tr",
        oa:postfix "ials. Some published studies suggest that intermed",
        oa:prefix "with dexlansoprazole. fig 1 12.5 Pharmacogenomics "
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: spl:pharmgx-spl-annotation-set-13

    Annotations: 
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-14>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-44>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:onResource <file:///home/rdb20/Downloads/d2rq-0.8.1/linkedSPLs-dump.nt#structuredProductLabelMetadata/1086a7b4-b89b-4bee-8120-5f752626c046>
    
    Types: 
        <http://purl.org/dc/dcmitype/Collection>
    
    
Individual: spl:pharmgx-spl-annotation-set-14

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-18>,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-17>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:onResource <file:///home/rdb20/Downloads/d2rq-0.8.1/linkedSPLs-dump.nt#structuredProductLabelMetadata/7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0>
    
    Types: 
        <http://purl.org/dc/dcmitype/Collection>
    
    
Individual: spl:pharmgx-spl-annotation-set-11

    Annotations: 
        oa:onResource <file:///home/rdb20/Downloads/d2rq-0.8.1/linkedSPLs-dump.nt#structuredProductLabelMetadata/c3248d43-3dd6-4ca9-afca-528c7abe0fce>,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-12>,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-11>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-51>,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-34>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-42>
    
    Types: 
        <http://purl.org/dc/dcmitype/Collection>
    
    
Individual: spl:pharmgx-spl-annotation-set-12

    Annotations: 
        oa:onResource <file:///home/rdb20/Downloads/d2rq-0.8.1/linkedSPLs-dump.nt#structuredProductLabelMetadata/03bec9ad-cd22-44d3-9b82-2796157de1d1>,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-13>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-43>
    
    Types: 
        <http://purl.org/dc/dcmitype/Collection>
    
    
Individual: spl:pharmgx-spl-annotation-set-17

    Annotations: 
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-25>,
        oa:onResource <file:///home/rdb20/Downloads/d2rq-0.8.1/linkedSPLs-dump.nt#structuredProductLabelMetadata/c95f0b0d-77ef-e753-be04-2228139df2d3>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-70>,
        oa:annotatedAt "2013-03-13"^^xsd:date
    
    Types: 
        <http://purl.org/dc/dcmitype/Collection>
    
    
Individual: spl:pharmgx-spl-annotation-set-18

    Annotations: 
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-49>,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-61>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-35>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:onResource <file:///home/rdb20/Downloads/d2rq-0.8.1/linkedSPLs-dump.nt#structuredProductLabelMetadata/217e52b5-3a7b-4bbe-af3c-b18de7d426c3>
    
    Types: 
        <http://purl.org/dc/dcmitype/Collection>
    
    
Individual: spl:pharmgx-spl-annotation-set-15

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-19>,
        oa:onResource <file:///home/rdb20/Downloads/d2rq-0.8.1/linkedSPLs-dump.nt#structuredProductLabelMetadata/407a372d-4448-4d53-afd4-eb0e74bbc336>
    
    Types: 
        <http://purl.org/dc/dcmitype/Collection>
    
    
Individual: spl:pharmgx-spl-annotation-set-16

    Annotations: 
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-48>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-54>,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-47>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-68>,
        oa:onResource <file:///home/rdb20/Downloads/d2rq-0.8.1/linkedSPLs-dump.nt#structuredProductLabelMetadata/ab047628-67d0-4a64-8d77-36b054969b44>,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-21>,
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-20>
    
    Types: 
        <http://purl.org/dc/dcmitype/Collection>
    
    
Individual: <urn:uuid:db49846d-52fe-4062-8d98-030fabc8b042>

    Annotations: 
        oa:hasSelector <urn:uuid:8fff69eb-fc1d-4c31-9deb-09bfd1da2bf3>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinicalPharmacology>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=217e52b5-3a7b-4bbe-af3c-b18de7d426c3>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: spl:pharmgx-spl-annotation-set-20

    Annotations: 
        oa:onResource <file:///home/rdb20/Downloads/d2rq-0.8.1/linkedSPLs-dump.nt#structuredProductLabelMetadata/d8275c2d-f42d-4f32-aa9f-03a202c8e99f>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:item <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-item-62>,
        oa:annotatedAt "2013-03-13"^^xsd:date
    
    Types: 
        <http://purl.org/dc/dcmitype/Collection>
    
    
Individual: <urn:uuid:1b830b10-8ac0-447d-b91a-2b76337ff76c>

    Annotations: 
        oa:hasSelector <urn:uuid:3764d067-0b68-46ff-bdb9-253672e163a6>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/precautions>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:78651351-7a49-4cf6-9a6b-1a0a0fe19c87>

    Annotations: 
        oa:hasSelector <urn:uuid:8719510f-bb69-433b-8d86-291ccec2b6a3>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/drugInteractions>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=49212741-389f-4112-94a9-d14ea2115825>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:b647d7f6-f1e3-443c-bbec-6a336ab2b87d>

    Annotations: 
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=128846a7-18c6-4bc4-b3a0-9aeed0e8b986>,
        oa:hasSelector <urn:uuid:5db4f1be-50b0-4813-8488-2e6078a155c0>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/dosageAndAdministration>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:ca086c56-a872-4a0c-b16e-06d067518318>

    Annotations: 
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1086a7b4-b89b-4bee-8120-5f752626c046>,
        oa:hasSelector <urn:uuid:36b51159-6227-4ac6-9b52-65de52e11fb3>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/warningsAndPrecautions>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:84cfe968-4129-4a76-9295-b2ae6b5d65d0>

    Annotations: 
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/precautions>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=87315917-3e54-44e6-bb64-2f722501c11b>,
        oa:hasSelector <urn:uuid:c5d898c2-b618-42ab-aeed-709bb377c86a>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:cc558dbc-ff13-4097-a348-6d6ca7c2079f>

    Annotations: 
        oa:hasSelector <urn:uuid:6eb1c899-5526-4df7-be46-1e8bf6bc7b27>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa3ed180-298a-4f9d-9d05-15182d7218bf>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/warningsAndPrecautions>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:22d02543-e2d0-4314-8c8f-502c5b339a35>

    Annotations: 
        oa:prefix "------------------- 5.1 Hypersensitivity Reaction ",
        oa:exact "Serious and sometimes fatal hypersensitivity reactions have been associated with ZIAGEN and other abacavir-containing products. Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir. Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of a hypersensitivity reaction. Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir. For HLA-B*5701-positive patients, treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances when the potential benefit outweighs the risk.",
        oa:postfix " HLA-B*5701-negative patients may develop a hypers"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:8fff69eb-fc1d-4c31-9deb-09bfd1da2bf3>

    Annotations: 
        oa:exact "Coadministration of ABILIFY with known inhibitors of CYP2D6, such as quinidine or fluoxetine in EMs, approximately doubles aripiprazole plasma exposure, and dose adjustment is needed [see DRUG INTERACTIONS (7.1)].",
        oa:prefix "rom a given dose of aripiprazole compared to EMs. ",
        oa:postfix " The mean elimination half-lives are about 75 hour"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:8e843bf8-61bb-4505-8f33-e4aa43a46576>

    Annotations: 
        oa:exact "In TRITON-TIMI 38 and the majority of the cohort studies, the combined group of patients with either intermediate or poor metabolizer status had a higher rate of cardiovascular events (death, myocardial infarction, and stroke) or stent thrombosis compared to extensive metabolizers. In CHARISMA and one cohort study, the increased event rate was observed only in poor metabolizers.",
        oa:postfix "",
        oa:prefix "n=1477), and in several published cohort studies. "
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:188ebbca-2fb3-42a1-ae11-98057e5ff6a7>

    Annotations: 
        oa:exact "Metastatic Breast Cancer Tamoxifen citrate tablets are effective in the treatment of metastatic breast cancer in women and men. In premenopausal women with metastatic breast cancer, tamoxifen is an alternative to oophorectomy or ovarian irradiation. Available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen therapy.",
        oa:prefix "INDICATIONS AND USAGE ",
        oa:postfix " Adjuvant Treatment of Breast Cancer Tamoxifen cit"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:0c213c3e-0047-4bc4-99fd-5e73583a8888>

    Annotations: 
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=040d010a-b1b2-4db7-905d-8aa7f1bab0cd>,
        oa:hasSelector <urn:uuid:61db4ff2-fb24-4ba2-99ef-de923a064300>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/adverseReactions>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:81a455a9-afb0-4e5e-b725-4a75299d8c4e>

    Annotations: 
        oa:postfix " 2.4 Use with Proton Pump Inhibitors (PPI) Avoid u",
        oa:prefix "armacology (12.3)]. 2.3 CYP2C19 Poor Metabolizers ",
        oa:exact "CYP2C19 poor metabolizer status is associated with diminished antiplatelet response to clopidogrel. Although a higher dose regimen in poor metabolizers increases antiplatelet response [see Clinical Pharmacology (12.5)], an appropriate dose regimen for this patient population has not been established."
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:3ae43b69-a16a-42ca-8ae4-472865d09c3d>

    Annotations: 
        oa:exact "Periodic determination of PT/INR is essential (seeDOSAGE AND ADMINISTRATION:Laboratory control). Numerous factors, alone or in combination, including changes in diet, medications, botanicals and genetic variations in the CYP2C9 and VKORC1 enzymes (seeCLINICAL PHARMACOLOGY,Pharmacogenomics) may influence the response of the patient to warfarin.",
        oa:prefix "PRECAUTIONS ",
        oa:postfix " Drug/Drug and Drug/Disease Interactions It is gen"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:38a27c57-7951-4d69-b448-d1c040f1735c>

    Annotations: 
        oa:hasSelector <urn:uuid:ecd730fc-6095-4549-8bdf-a6d437097f73>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=16bda7b5-a5a5-4478-9df3-beb396bd677f>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/warnings>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:5f327aca-6f90-45b1-a8c9-4e93d6132568>

    Annotations: 
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=128846a7-18c6-4bc4-b3a0-9aeed0e8b986>,
        oa:hasSelector <urn:uuid:5adc358c-b78a-4ebe-9f16-6e80c9eefef1>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/dosageAndAdministration>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:fb3f4b4b-f0b6-43f1-99e0-86459c27c00c>

    Annotations: 
        oa:hasSelector <urn:uuid:a8f32294-e016-46d0-877f-7683d960d5c2>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa3ed180-298a-4f9d-9d05-15182d7218bf>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/warningsAndPrecautions>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:9068dfb5-8fc3-403c-95a1-28e54f4cc5ff>

    Annotations: 
        oa:exact "When therapy with ZIAGEN has been discontinued for reasons other than symptoms of a hypersensitivity reaction, and if reinitiation of ZIAGEN or any other abacavir-containing product is under consideration, carefully evaluate the reason for discontinuation of ZIAGEN to ensure that the patient did not have symptoms of a hypersensitivity reaction. If the patient is of unknown HLA-B*5701 status, screening for the allele is recommended prior to reinitiation of ZIAGEN. If hypersensitivity cannot be ruled out, DO NOT reintroduce ZIAGEN or any other abacavir-containing product. Even in the absence of the HLA-B*5701 allele, it is important to permanently discontinue abacavir and not rechallenge with abacavir if a hypersensitivity reaction cannot be ruled out on clinical grounds, due to the potential for a severe or even fatal reaction.",
        oa:postfix " If symptoms consistent with hypersensitivity are ",
        oa:prefix "y include life-threatening hypotension and death. "
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:e9193721-82c5-49eb-82e8-f08456eb60c0>

    Annotations: 
        oa:hasSelector <urn:uuid:c151b711-e27a-441f-9a45-eda717e46232>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinicalPharmacology>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:f2973cae-d394-44a3-a7a3-a43183bd99fc>

    Annotations: 
        oa:hasSelector <urn:uuid:e8d3003b-1a80-4c88-9baa-53473351b933>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ab047628-67d0-4a64-8d77-36b054969b44>,
        oa:hasSelector <urn:uuid:daaca653-922b-4735-b084-e8ec2d3fa359>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/dosageAndAdministration>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:0f334c36-0d0d-45c6-a84b-ebcbffa95420>

    Annotations: 
        oa:hasSelector <urn:uuid:188ebbca-2fb3-42a1-ae11-98057e5ff6a7>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0>,
        oa:hasSelector <urn:uuid:f04f09ba-0ac5-45b4-8ee8-ccafdaae09cf>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/indicationsAndUsage>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:2e332e4e-ee0b-4b7e-a8a8-fda9887c4f4e>

    Annotations: 
        oa:prefix "DOSAGE AND ADMINISTRATION ",
        oa:postfix " Renal Homotransplantation The dose of azathioprin",
        oa:exact "TPMT TESTING CANNOT SUBSTITUTE FOR COMPLETE BLOOD COUNT (CBC) MONITORING IN PATIENTS RECEIVING AZATHIOPRINE TABLETS. TPMT genotyping or phenotyping can be used to identify patients with absent or reduced TPMT activity. Patients with low or absent TPMT activity are at an increased risk of developing severe, life-threatening myelotoxicity from azathioprine tablets if conventional doses are given. Physicians may consider alternative therapies for patients who have low or absent TPMT activity (homozygous for non-functional alleles). Azathioprine tablets should be administered with caution to patients having one non-functional allele (heterozygous) who are at risk for reduced TPMT activity that may lead to toxicity if conventional doses are given. Dosage reduction is recommended in patients with reduced TPMT activity. Early drug discontinuation may be considered in patients with abnormal CBC results that do not respond to dose reduction."
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:601b54f5-c4c8-4dca-8dec-c6f57fe46d1f>

    Annotations: 
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/precautions>,
        oa:hasSelector <urn:uuid:3ae43b69-a16a-42ca-8ae4-472865d09c3d>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:36b51159-6227-4ac6-9b52-65de52e11fb3>

    Annotations: 
        oa:exact "Clopidogrel is a prodrug. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. The metabolism of clopidogrel to its active metabolite can be impaired by genetic variations in CYP2C19 [see Boxed Warning] and by concomitant medications that interfere with CYP2C19. Avoid concomitant use of Plavix and drugs that inhibit CYP2C19 activity. Co-administration of Plavix with omeprazole, a proton pump inhibitor that is an inhibitor of CYP2C19, reduces the pharmacological activity of Plavix if given concomitantly or if given 12 hours apart",
        oa:prefix "latelet Activity Due to Impaired CYP2C19 Function ",
        oa:postfix " [see Drug Interactions (7.1)]. 5.2 General Risk o"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:1ac4c4a2-d387-4e86-8cf1-0a1ed7c99839>

    Annotations: 
        oa:postfix "S] 8.4 Pediatric Use The safety and effectiveness ",
        oa:prefix "ry depression in the neonate. 8.3 Nursing Mothers ",
        oa:exact "Codeine is secreted into human milk. In women with normal codeine metabolism (normal CYP2D6 activity), the amount of codeine secreted into human milk is low and dose-dependent. However, some women are ultra-rapid metabolizers of codeine. These women achieve higher-than-expected serum levels of codeine’s active metabolite, morphine, leading to higher-than-expected levels of morphine in breast milk and potentially dangerously high serum morphine levels in their breastfed infants. Therefore, maternal use of codeine can potentially lead to serious adverse reactions, including death, in nursing infants. The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese and Japanese, 0.5 to 1% in Hispanics, 1 to 10% in Caucasians, 3% in African Americans, and 16 to 28% in North Africans, Ethiopians, and Arabs. Data are not available for other ethnic groups. The risk of infant exposure to codeine and morphine through breast milk should be weighed against the benefits of breastfeeding for both the mother and the baby. Caution should be exercised when codeine is administered to a nursing woman. If a codeine containing product is selected, the lowest dose should be prescribed for the shortest period of time to achieve the desired clinical effect. Mothers using codeine should be informed about when to seek immediate medical care and how to identify the signs and symptoms of neonatal toxicity, such as drowsiness or sedation, difficulty breastfeeding, breathing difficulties, and decreased tone, in their baby. Nursing mothers who are ultra-rapid metabolizers may also experience overdose symptoms such as extreme sleepiness, confusion, or shallow breathing. Prescribers should closely monitor mother-infant pairs and notify treating pediatricians about the use of codeine during breastfeeding. [see 5 WARNINGS AND PRECAUTION"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:e8d3003b-1a80-4c88-9baa-53473351b933>

    Annotations: 
        oa:exact "Table 1 displays three ranges of expected maintenance warfarin sodium doses observed in subgroups of patients having different combinations of CYP2C9 and VKORC1 gene variants [see Clinical Pharmacology (12.5)]. If the patient's CYP2C9 and/or VKORC1 genotype are known, consider these ranges in choosing the initial dose. Patients with CYP2C9 *1/*3, *2/*2, *2/*3, and *3/*3 may require more prolonged time (>2 to 4 weeks) to achieve maximum INR effect for a given dosage regimen than patients without these CYP variants.",
        oa:postfix " 2.4 Monitoring to Achieve Optimal Anticoagulation",
        oa:prefix "ng Recommendations with Consideration of Genotype "
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:61db4ff2-fb24-4ba2-99ef-de923a064300>

    Annotations: 
        oa:prefix "ocytic anemia and/or bleeding have been reported. ",
        oa:postfix " Gastrointestinal Nausea and vomiting may occur wi",
        oa:exact "TPMT genotyping or phenotyping can help identify patients with low or absent TPMT activity (homozygous for non-functional alleles) who are at increased risk for severe, life-threatening myelosuppression from azathioprine tablets (see CLINICAL PHARMACOLOGY, WARNINGS and PRECAUTIONS: Laboratory Tests). Death associated with pancytopenia has been reported in patients with absent TPMT activity receiving azathioprine.6, 20"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:928c5b11-9b22-4cd7-8d3c-e4a2a134d0df>

    Annotations: 
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinicalPharmacology>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=217e52b5-3a7b-4bbe-af3c-b18de7d426c3>,
        oa:hasSelector <urn:uuid:e86f13d0-b9d2-457b-baec-807a8111ffd9>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:f2470e11-f784-402d-83a5-3597a9ce905a>

    Annotations: 
        oa:exact "CYP2C19 is involved in the formation of both the active metabolite and the 2-oxo-clopidogrel intermediate metabolite. Clopidogrel active metabolite pharmacokinetics and antiplatelet effects, as measured by ex vivo platelet aggregation assays, differ according to CYP2C19 genotype. Genetic variants of other CYP450 enzymes may also affect the formation of clopidogrel’s active metabolite. The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and *3 alleles are nonfunctional. CYP2C19*2 and *3 account for the majority of reduced function alleles in white (85%) and Asian (99%) poor metabolizers. Other alleles associated with absent or reduced metabolism are less frequent, and include, but are not limited to, CYP2C19*4, *5, *6, *7, and *8. A patient with poor metabolizer status will possess two loss-of-function alleles as defined above. Published frequencies for poor CYP2C19 metabolizer genotypes are approximately 2% for whites, 4% for blacks and 14% for Chinese. Tests are available to determine a patient’s CYP2C19 genotype.   A crossover study in 40 healthy subjects, 10 each in the four CYP2C19 metabolizer groups, evaluated pharmacokinetic and antiplatelet responses using 300 mg followed by 75 mg per day and 600 mg followed by 150 mg per day, each for a total of 5 days. Decreased active metabolite exposure and diminished inhibition of platelet aggregation were observed in the poor metabolizers as compared to the other groups. When poor metabolizers received the 600 mg/150 mg regimen, active metabolite exposure and antiplatelet response were greater than with the 300 mg/75 mg regimen (see Table 3). An appropriate dose regimen for this patient population has not been established in clinical outcome tr",
        oa:postfix "ials. Some published studies suggest that intermed",
        oa:prefix "with dexlansoprazole. fig 1 12.5 Pharmacogenomics "
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:85f68655-42ae-482f-93f5-e5809f810959>

    Annotations: 
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1086a7b4-b89b-4bee-8120-5f752626c046>,
        oa:hasSelector <urn:uuid:225fe84d-6164-4a12-a784-e2bd5fc0a10a>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/warningsAndPrecautions>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:daaca653-922b-4735-b084-e8ec2d3fa359>

    Annotations: 
        oa:prefix "has passed [see Dosage and Administration (2.2)]. ",
        oa:postfix " Dosing Recommendations with Consideration of Geno",
        oa:exact "Dosing Recommendations without Consideration of Genotype If the patient's CYP2C9 and VKORC1 genotypes are not known, the initial dose of warfarin sodium is usually 2 to 5 mg once daily. Determine each patient's dosing needs by close monitoring of the INR response and consideration of the indication being treated. Typical maintenance doses are 2 to 10 mg once daily."
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:e63291ed-b7d7-4025-b329-9ecc563cd5ac>

    Annotations: 
        oa:prefix "Drug Interactions ",
        oa:exact "Use with Allopurinol One of the pathways for inactivation of azathioprine is inhibited by allopurinol. Patients receiving azathioprine and allopurinol concomitantly should have a dose reduction of azathioprine, to approximately 1/3 to 1/4 the usual dose. It is recommended that a further dose reduction or alternative therapies be considered for patients with low or absent TPMT activity receiving azathioprine and allopurinol because both TPMT and XO inactivation pathways are affected (see CLINICAL PHARMACOLOGY, WARNINGS, PRECAUTIONS: Laboratory Tests and ADVERSE REACTIONS sections)",
        oa:postfix ". Use with Aminosalicylates There is in vitro evid"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:e2dd5095-0b2d-4923-ba2a-0ddcd41d0ee7>

    Annotations: 
        oa:hasSelector <urn:uuid:2c65c4ad-7d7d-4275-96ed-ed3f89f620fa>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/useInSpecificPopulations>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa3ed180-298a-4f9d-9d05-15182d7218bf>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:d3019015-d24b-4a80-83b3-4b72216e2f2e>

    Annotations: 
        oa:exact "Periodic determination of PT/INR is essential. (See DOSAGE AND ADMINISTRATION, Laboratory Control.) Numerous factors, alone or in combination including changes in diet, medications, botanicals, and genetic variations in the CYP2C9 and VKORC1 enzymes (see CLINICAL PHARMACOLOGY, Pharmacogenomics) may influence the response of the patient to warfarin.",
        oa:prefix "PRECAUTIONS ",
        oa:postfix " Drug-Drug and Drug-Disease Interactions It is gen"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:20ee62b5-5db5-4498-ac4f-6930cbf79cd3>

    Annotations: 
        oa:hasSelector <urn:uuid:91026743-fb76-4773-908e-9debcb491286>,
        oa:hasSelector <urn:uuid:fc44cf07-fcf4-44ff-9c08-0b8e237e9974>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/boxedWarning>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d021d9b-c0b8-41a3-a99b-37f50d2a20ae>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:14486594-722d-4abd-890e-1dc51486baed>

    Annotations: 
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=128846a7-18c6-4bc4-b3a0-9aeed0e8b986>,
        oa:hasSelector <urn:uuid:51a1c204-1d9f-4956-a9df-ea178aeec2bb>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/dosageAndAdministration>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:0b1392ad-f755-4c05-8f1c-7fd804abb04b>

    Annotations: 
        oa:exact "CYP2C9 and VKORC1 Polymorphisms The S-enantiomer of warfarin is mainly metabolized to 7-hydroxywarfarin by CYP2C9, a polymorphic enzyme. The variant alleles, CYP2C9*2 and CYP2C9*3, result in decreased in vitro CYP2C9 enzymatic 7-hydroxylation of S-warfarin. The frequencies of these alleles in Caucasians are approximately 11% and 7% for CYP2C9*2 and CYP2C9*3, respectively. Other CYP2C9 alleles associated with reduced enzymatic activity occur at lower frequencies, including *5, *6, and *11 alleles in populations of African ancestry and *5, *9, and *11 alleles in Caucasians. Warfarin reduces the regeneration of vitamin K from vitamin K epoxide in the vitamin K cycle through inhibition of VKOR, a multiprotein enzyme complex. Certain single nucleotide polymorphisms in the VKORC1 gene (e.g., –1639G>A) have been associated with variable warfarin dose requirements. VKORC1 and CYP2C9 gene variants generally explain the largest proportion of known variability in warfarin dose requirements. CYP2C9 and VKORC1 genotype information, when available, can assist in selection of the initial dose of warfari",
        oa:prefix "rement with increasing age. 12.5 Pharmacogenomics ",
        oa:postfix "n"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:b9dd7291-c77b-4b82-8a60-cef55c9a863d>

    Annotations: 
        oa:hasSelector <urn:uuid:81a455a9-afb0-4e5e-b725-4a75299d8c4e>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03bec9ad-cd22-44d3-9b82-2796157de1d1>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/dosageAndAdministration>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:7773a273-d4c8-4dec-ba9e-597929b491a7>

    Annotations: 
        oa:hasSelector <urn:uuid:7017174c-c35d-4705-b332-942c590508b5>,
        oa:hasSelector <urn:uuid:9068dfb5-8fc3-403c-95a1-28e54f4cc5ff>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/warningsAndPrecautions>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:dc49f0aa-f036-4231-ac41-b5d721aa8e7a>

    Annotations: 
        oa:exact "CYP2C19 is involved in the formation of both the active metabolite and the 2-oxo-clopidogrel intermediate metabolite. Clopidogrel active metabolite pharmacokinetics and antiplatelet effects, as measured by ex vivo platelet aggregation assays, differ according to CYP2C19 genotype. Genetic variants of other CYP450 enzymes may also affect the formation of clopidogrel’s active metabolite. The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and *3 alleles are nonfunctional. CYP2C19*2 and *3 account for the majority of reduced function alleles in white (85%) and Asian (99%) poor metabolizers. Other alleles associated with absent or reduced metabolism are less frequent, and include, but are not limited to, CYP2C19*4, *5, *6, *7, and *8. A patient with poor metabolizer status will possess two loss-of-function alleles as defined above. Published frequencies for poor CYP2C19 metabolizer genotypes are approximately 2% for whites, 4% for blacks and 14% for Chinese. Tests are available to determine a patient’s CYP2C19 genotype.   A crossover study in 40 healthy subjects, 10 each in the four CYP2C19 metabolizer groups, evaluated pharmacokinetic and antiplatelet responses using 300 mg followed by 75 mg per day and 600 mg followed by 150 mg per day, each for a total of 5 days. Decreased active metabolite exposure and diminished inhibition of platelet aggregation were observed in the poor metabolizers as compared to the other groups. When poor metabolizers received the 600 mg/150 mg regimen, active metabolite exposure and antiplatelet response were greater than with the 300 mg/75 mg regimen (see Table 3). An appropriate dose regimen for this patient population has not been established in clinical outcome tr",
        oa:postfix "ials. Some published studies suggest that intermed",
        oa:prefix "with dexlansoprazole. fig 1 12.5 Pharmacogenomics "
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: spl:pharmgx-spl-annotation-body-6

    Annotations: 
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Azathioprine>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "AZATHIOPRINE",
        spl:PharmacodynamicImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00993>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "TPMT"
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-7

    Annotations: 
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Azathioprine>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "AZATHIOPRINE",
        spl:PharmacodynamicImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00993>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "TPMT"
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-8

    Annotations: 
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Azathioprine>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "AZATHIOPRINE",
        spl:PharmacodynamicImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00993>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "TPMT"
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-9

    Annotations: 
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "CITALOPRAM",
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2C19",
        spl:PharmacodynamicImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased>,
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2C19>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00215>
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: <urn:uuid:dafccef8-8cf3-4df3-ab5a-b3631d7a9d27>

    Annotations: 
        oa:prefix "tabolizers [see Dosage and Administration (2.3)]. ",
        oa:exact "WARNING: DIMINISHED EFFECTIVENESS IN POOR METABOLIZERS   See full prescribing information for complete boxed warning.   Effectiveness of clopidogrel bisulfate depends on activation to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19. (5.1) Poor metabolizers treated with clopidogrel bisulfate at recommended doses exhibit higher cardiovascular event rates following acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) than patients with normal CYP2C19 function. (12.5) Tests are available to identify a patient's CYP2C19 genotype and can be used as an aid in determining therapeutic strategy. (12.5) Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers. (2.3, 5.",
        oa:postfix "1)"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:b849f98a-a8dc-4acd-8f4f-ea0b45c7fa5e>

    Annotations: 
        oa:exact "In premenopausal women with metastatic breast cancer, tamoxifen is an alternative to oophorectomy or ovarian irradiation. Available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen therapy.",
        oa:prefix "ent of metastatic breast cancer in women and men. ",
        oa:postfix " Adjuvant Treatment of Breast Cancer Tamoxifen cit"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:2c65c4ad-7d7d-4275-96ed-ed3f89f620fa>

    Annotations: 
        oa:postfix "S] 8.4 Pediatric Use The safety and effectiveness ",
        oa:prefix "id-induced respiratory depression in the neonate. ",
        oa:exact "8.3 Nursing Mothers Codeine is secreted into human milk. In women with normal codeine metabolism (normal CYP2D6 activity), the amount of codeine secreted into human milk is low and dose-dependent. However, some women are ultra-rapid metabolizers of codeine. These women achieve higher-than-expected serum levels of codeine’s active metabolite, morphine, leading to higher-than-expected levels of morphine in breast milk and potentially dangerously high serum morphine levels in their breastfed infants. Therefore, maternal use of codeine can potentially lead to serious adverse reactions, including death, in nursing infants. The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese and Japanese, 0.5 to 1% in Hispanics, 1 to 10% in Caucasians, 3% in African Americans, and 16 to 28% in North Africans, Ethiopians, and Arabs. Data are not available for other ethnic groups. The risk of infant exposure to codeine and morphine through breast milk should be weighed against the benefits of breastfeeding for both the mother and the baby. Caution should be exercised when codeine is administered to a nursing woman. If a codeine containing product is selected, the lowest dose should be prescribed for the shortest period of time to achieve the desired clinical effect. Mothers using codeine should be informed about when to seek immediate medical care and how to identify the signs and symptoms of neonatal toxicity, such as drowsiness or sedation, difficulty breastfeeding, breathing difficulties, and decreased tone, in their baby. Nursing mothers who are ultra-rapid metabolizers may also experience overdose symptoms such as extreme sleepiness, confusion, or shallow breathing. Prescribers should closely monitor mother-infant pairs and notify treating pediatricians about the use of codeine during breastfeeding. [see 5 WARNINGS AND PRECAUTION"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:936119ff-10f0-4603-8149-ae256f1fce69>

    Annotations: 
        oa:exact "A crossover study in 40 healthy subjects, 10 each in the four CYP2C19 metabolizer groups, evaluated pharmacokinetic and antiplatelet responses using 300 mg followed by 75 mg per day and 600 mg followed by 150 mg per day, each for a total of 5 days. Decreased active metabolite exposure and diminished inhibition of platelet aggregation were observed in the poor metabolizers as compared to the other groups. When poor metabolizers received the 600 mg/150 mg regimen, active metabolite exposure and antiplatelet response were greater than with the 300 mg/75 mg regimen (see Table 3)",
        oa:prefix "e to determine a patient’s CYP2C19 genotype.   ",
        oa:postfix ". An appropriate dose regimen for this patient pop"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:fe9b09c6-181b-4d57-87a7-f4c68c3dbbdb>

    Annotations: 
        oa:exact "Azathioprine is metabolized to 6-mercaptopurine (6-MP). Both compounds are rapidly eliminated from blood and are oxidized or methylated in erythrocytes and liver; no azathioprine or mercaptopurine is detectable in urine after 8 hours. Activation of 6-mercaptopurine occurs via hypoxanthine-guanine phosphoribosyltransferase (HGPRT) and a series of multi-enzymatic processes involving kinases to form 6-thioguanine nucleotides (6TGNs) as major metabolites (See Metabolism Scheme in Figure 1). The cytotoxicity of azathioprine is due, in part, to the incorporation of 6-TGN into DNA. 6-MP undergoes two major inactivation routes (Figure 1). One is thiol methylation, which is catalyzed by the enzyme thiopurine S-methyltransferase (TPMT), to form the inactive metabolite methyl-6-MP (6-MeMP). TPMT activity is controlled by a genetic polymorphism. 1,2,3 For Caucasians and African Americans, approximately 10% of the population inherit one non-functional TPMT allele (heterozygous) conferring intermediate TPMT activity, and 0.3% inherit two TPMT non-functional alleles (homozygous) for low or absent TPMT activity. Non-functional alleles are less common in Asians. TPMT activity correlates inversely with 6TGN levels in erythrocytes and presumably other hematopoietic tissues, since these cells have negligible xanthine oxidase (involved in the other inactivation pathway) activities, leaving TPMT methylation as the only inactivation pathway. Patients with intermediate TPMT activity may be at increased risk of myelotoxicity if receiving conventional doses of azathioprine. Patients with low or absent TPMT activity are at an increased risk of developing severe, life-threatening myelotoxicity if receiving conventional doses of azathioprine.4-9 TPMT genotyping or phenotyping (red blood cell TPMT activity) can help identify patients who are at an increased risk for developing azathioprine toxicity.2, 3, 7, 8, 9 Accurate phenotyping (red blood cell TPMT activity) results are not possible in patients who have received recent blood transfusions. (See WARNINGS, PRECAUTIONS: Drug Interactions, PRECAUTIONS: Laboratory Tests and ADVERSE REACTIONS sections)",
        oa:postfix ". Figure 1. Metabolism pathway of azathioprine : c",
        oa:prefix " and are partially dialyzable. (See OVERDOSAGE ). "
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:a07ef183-8bab-44bf-81e8-ffbc5bbb9343>

    Annotations: 
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb>,
        oa:hasSelector <urn:uuid:22d02543-e2d0-4314-8c8f-502c5b339a35>,
        oa:hasSelector <urn:uuid:6ab3e2fa-7238-46ba-8efe-4abe862af5da>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/warningsAndPrecautions>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: spl:pharmgx-spl-annotation-body-5

    Annotations: 
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB01048>,
        spl:PharmacodynamicImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "ABACAVIR",
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "HLA-B*5701"
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-4

    Annotations: 
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB01048>,
        spl:PharmacodynamicImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacodynamicImpact>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "ABACAVIR",
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "HLA-B*5701"
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-3

    Annotations: 
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MonitoringRecommendation>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "VKORC1",
        spl:MonitoringRecommendation <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#change-in-monitoring>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Warfarin>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00682>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#VKORC1>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "WARFARIN"
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-2

    Annotations: 
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2C9>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MonitoringRecommendation>,
        spl:MonitoringRecommendation <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#change-in-monitoring>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Warfarin>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00682>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "WARFARIN",
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2C9"
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-1

    Annotations: 
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2D6",
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MonitoringRecommendation>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "CODEINE",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2D6>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00318>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        spl:MonitoringRecommendation <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended>
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: <urn:uuid:8a673cdc-6d29-4266-b3db-24121dd35b09>

    Annotations: 
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb>,
        oa:hasSelector <urn:uuid:f7a7d71c-cb3e-47d8-877e-1bbb7ae9825c>,
        oa:hasSelector <urn:uuid:951e98d8-3093-462f-a9bd-88c34d7b6969>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/warningsAndPrecautions>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:f495bfa8-e0aa-47d7-aa62-e68fb4856e3b>

    Annotations: 
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/precautions>,
        oa:hasSelector <urn:uuid:9db528e5-494b-4fa0-8251-26d67286feba>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d35df36-1a19-4559-91fe-252b7082295b>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:089ec7d8-3734-4e40-9ebb-f69d6f34cc1e>

    Annotations: 
        oa:exact "Azathioprine tablets should be administered with caution to patients having one non-functional allele (heterozygous) who are at risk for reduced TPMT activity that may lead to toxicity if conventional doses are given. Dosage reduction is recommended in patients with reduced TPMT activity. Early drug discontinuation may be considered in patients with abnormal CBC results that do not respond to dose reduction.",
        oa:prefix "activity (homozygous for non-functional alleles). ",
        oa:postfix " Renal Homotransplantation The dose of azathioprin"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:336086ef-054e-4242-978c-cc0a89233278>

    Annotations: 
        oa:exact "Identification of risk factors for bleeding and certain genetic variations in CYP2C9 and VKORC1 in a patient may increase the need for more frequent INR monitoring and the use of lower warfarin doses (see CLINICAL PHARMACOLOGY:PharmacokineticsMetabolismandDOSAGE AND ADMINISTRATION).",
        oa:prefix "ECAUTIONS) and long duration of warfarin therapy. ",
        oa:postfix " Bleeding is more likely to occur during the start"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: spl:pharmgx-spl-annotation-item-1

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:hasTarget <urn:uuid:e8e1d299-f0b2-4e29-aa27-8c33404b1e9c>,
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-1>,
        oa:annotatedAt "2013-03-13"^^xsd:date
    
    Types: 
        oa:Annotation
    
    
Individual: <urn:uuid:6bff9d47-ca18-4047-8e7f-2523fb3108c5>

    Annotations: 
        oa:exact "Azathioprine is metabolized to 6-mercaptopurine (6-MP). Both compounds are rapidly eliminated from blood and are oxidized or methylated in erythrocytes and liver; no azathioprine or mercaptopurine is detectable in urine after 8 hours. Activation of 6-mercaptopurine occurs via hypoxanthine-guanine phosphoribosyltransferase (HGPRT) and a series of multi-enzymatic processes involving kinases to form 6-thioguanine nucleotides (6TGNs) as major metabolites (See Metabolism Scheme in Figure 1). The cytotoxicity of azathioprine is due, in part, to the incorporation of 6-TGN into DNA. 6-MP undergoes two major inactivation routes (Figure 1). One is thiol methylation, which is catalyzed by the enzyme thiopurine S-methyltransferase (TPMT), to form the inactive metabolite methyl-6-MP (6-MeMP). TPMT activity is controlled by a genetic polymorphism. 1,2,3 For Caucasians and African Americans, approximately 10% of the population inherit one non-functional TPMT allele (heterozygous) conferring intermediate TPMT activity, and 0.3% inherit two TPMT non-functional alleles (homozygous) for low or absent TPMT activity. Non-functional alleles are less common in Asians. TPMT activity correlates inversely with 6TGN levels in erythrocytes and presumably other hematopoietic tissues, since these cells have negligible xanthine oxidase (involved in the other inactivation pathway) activities, leaving TPMT methylation as the only inactivation pathway. Patients with intermediate TPMT activity may be at increased risk of myelotoxicity if receiving conventional doses of azathioprine. Patients with low or absent TPMT activity are at an increased risk of developing severe, life-threatening myelotoxicity if receiving conventional doses of azathioprine.4-9 TPMT genotyping or phenotyping (red blood cell TPMT activity) can help identify patients who are at an increased risk for developing azathioprine toxicity.2, 3, 7, 8, 9 Accurate phenotyping (red blood cell TPMT activity) results are not possible in patients who have received recent blood transfusions. (See WARNINGS, PRECAUTIONS: Drug Interactions, PRECAUTIONS: Laboratory Tests and ADVERSE REACTIONS sections)",
        oa:postfix ". Figure 1. Metabolism pathway of azathioprine : c",
        oa:prefix " and are partially dialyzable. (See OVERDOSAGE ). "
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: spl:pharmgx-spl-annotation-item-64

    Annotations: 
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-64>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasTarget <urn:uuid:75eb6545-f4fb-46e0-aacc-69757039f3d6>
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-63

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:hasTarget <urn:uuid:14486594-722d-4abd-890e-1dc51486baed>,
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-63>,
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-2

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-2>,
        oa:hasTarget <urn:uuid:2d1a6a6a-8aae-493c-b19e-1a1641fa2b41>
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-66

    Annotations: 
        oa:hasTarget <urn:uuid:ffa36f01-b3f5-47ae-ae5d-cb5a19daf790>,
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-66>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-3

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:hasTarget <urn:uuid:f495bfa8-e0aa-47d7-aa62-e68fb4856e3b>,
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-3>
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-65

    Annotations: 
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-65>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasTarget <urn:uuid:38a27c57-7951-4d69-b448-d1c040f1735c>
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-4

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-4>,
        oa:hasTarget <urn:uuid:036d5eb3-2c0b-4572-9df2-0b08bc69c1b4>
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-60

    Annotations: 
        oa:hasTarget <urn:uuid:c1b5873b-83ed-48de-95bb-4cbb216ccea5>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-60>,
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date
    
    Types: 
        oa:Annotation
    
    
Individual: <urn:uuid:850a3758-6d57-43b7-b00f-7031d9cc91af>

    Annotations: 
        oa:postfix "2.3)]. Routine use of loading doses is not recomme",
        oa:exact "2.3 Initial and Maintenance Dosing The appropriate initial dosing of warfarin sodium varies widely for different patients. Not all factors responsible for warfarin dose variability are known, and the initial dose is influenced by: •Clinical factors including age, race, body weight, sex, concomitant medications, and comorbidities •Genetic factors (CYP2C9 and VKORC1 genotypes) [see Clinical Pharmacology (12.5)] Select the initial dose based on the expected maintenance dose, taking into account the above factors. Modify this dose based on consideration of patient-specific clinical factors. Consider lower initial and maintenance doses for elderly and/or debilitated patients and in Asian patients [see Use in Specific Populations (8.5) and Clinical Pharmacology (1",
        oa:prefix "men (INR 2.0-3.0) may be used for these patients. "
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:293d0fa9-a023-46c6-9662-879287c1a9f2>

    Annotations: 
        oa:exact "Clopidogrel  bisulfate at recommended doses forms less of that metabolite and has a smaller effect on platelet function in patients who are CYP2C19 poor metabolizers.  Poor metabolizers with acute coronary syndrome or undergoing percutaneous coronary intervention treated with clopidogrel bisulfate at recommended doses exhibit higher cardiovascular event rates than do patients with normal CYP2C19 function. Tests are available to identify a patient's CYP2C19 genotype; these tests can be used as an aid in determining therapeutic strategy [see Clinical Pharmacology (12.5)]. Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers [see Dosage and Administration",
        oa:postfix " (2.3)]. WARNING: DIMINISHED EFFECTIVENESS IN POOR",
        oa:prefix "lly CYP2C19 [see Warnings and Precautions (5.1)]. "
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: spl:pharmgx-spl-annotation-item-62

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-62>,
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasTarget <urn:uuid:e5dfedf3-0240-4fc5-9ca1-6489d2723c34>
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-61

    Annotations: 
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-61>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasTarget <urn:uuid:db49846d-52fe-4062-8d98-030fabc8b042>
    
    Types: 
        oa:Annotation
    
    
Individual: <urn:uuid:dd236914-a400-409f-88b0-0d372e66de1e>

    Annotations: 
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/boxedWarning>,
        oa:hasSelector <urn:uuid:72e5d6f1-23a1-45b7-bcd9-dfeb7c4d7541>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d021d9b-c0b8-41a3-a99b-37f50d2a20ae>,
        oa:hasSelector <urn:uuid:464bfaec-724a-4e93-8ce9-d67bff139e75>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:8adfb52c-bb5e-411c-859c-bcf62b921dc3>

    Annotations: 
        oa:exact "When therapy with ZIAGEN has been discontinued for reasons other than symptoms of a hypersensitivity reaction, and if reinitiation of ZIAGEN or any other abacavir-containing product is under consideration, carefully evaluate the reason for discontinuation of ZIAGEN to ensure that the patient did not have symptoms of a hypersensitivity reaction. If the patient is of unknown HLA-B*5701 status, screening for the allele is recommended prior to reinitiation of ZIAGEN. If hypersensitivity cannot be ruled out, DO NOT reintroduce ZIAGEN or any other abacavir-containing product. Even in the absence of the HLA-B*5701 allele, it is important to permanently discontinue abacavir and not rechallenge with abacavir if a hypersensitivity reaction cannot be ruled out on clinical grounds, due to the potential for a severe or even fatal reaction.",
        oa:postfix " If symptoms consistent with hypersensitivity are ",
        oa:prefix "y include life-threatening hypotension and death. "
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:b9bbb66e-7a10-49fb-91e4-9a2c7b770e73>

    Annotations: 
        oa:exact "Citalopram causes dose-dependent QTc prolongation, an ECG abnormality that has been associated with torsade de pointes (TdP), ventricular tachycardia, and sudden death, all of which have been observed in postmarketing reports for citalopram. Individually corrected QTc (QTcNi) interval was evaluated in a randomized, placebo and active (moxifloxacin 400 mg) controlled cross-over, escalating multiple-dose study in 119 healthy subjects. The maximum mean (upper bound of the 95% one-sided confidence interval) difference from placebo were 8.5 (10.8) and 18.5 (21.0) msec for 20 mg and 60 mg citalopram, respectively. Based on the established exposure-response relationship, the predicted QTcNi change from placebo (upper bound of the 95% one-sided confidence interval) under the Cmax for the dose of 40 mg is 12.6 (14.3) msec. Because of the risk of QTc prolongation at higher citalopram doses, it is recommended that citalopram should not be given at doses above 40 mg/day. It is recommended that citalopram should not be used in patients with congenital long QT syndrome, bradycardia, hypokalemia or hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure. Citalopram should also not be used in patients who are taking other drugs that prolong the QTc interval. Such drugs include Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications, antipsychotic medications (e.g., chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to prolong the QTc interval (e.g., pentamidine, levomethadyl acetate, methadone). The citalopram dose should be limited in certain populations. The maximum dose should be limited to 20 mg/day in patients who are CYP2C19 poor metabolizers or those patients who may be taking concomitant cimetidine or another CYP2C19 inhibitor, since higher citalopram exposures would be expected. The maximum dose should also be limited to 20 mg/day in patients with hepatic impairment and in patients who are greater than 60 years of age because of expected higher exposures.",
        oa:prefix " overdose. QT-Prolongation and Torsade de Pointes ",
        oa:postfix " Electrolyte and/or ECG monitoring is recommended "
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: spl:pharmgx-spl-annotation-body-71

    Annotations: 
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DoseSelectionRecommendation>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "VKORC1",
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Warfarin>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00682>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        spl:DoseSelectionRecommendation <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "WARFARIN",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#VKORC1>
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: <urn:uuid:b28f4365-d26c-4930-b3b0-ba0cf014fb09>

    Annotations: 
        oa:hasSelector <urn:uuid:ac6f461f-9c5c-4bca-98ef-55b7c54b667c>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c3248d43-3dd6-4ca9-afca-528c7abe0fce>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinicalPharmacology>,
        oa:hasSelector <urn:uuid:dc49f0aa-f036-4231-ac41-b5d721aa8e7a>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: spl:pharmgx-spl-annotation-body-70

    Annotations: 
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DoseSelectionRecommendation>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "VKORC1",
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Warfarin>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00682>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        spl:DoseSelectionRecommendation <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "WARFARIN",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#VKORC1>
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: <urn:uuid:8719510f-bb69-433b-8d86-291ccec2b6a3>

    Annotations: 
        oa:exact "One of the pathways for inactivation of azathioprine is inhibited by allopurinol. Patients receiving azathioprine and allopurinol concomitantly should have a dose reduction of azathioprine, to approximately 1/3 to 1/4 the usual dose. It is recommended that a further dose reduction or alternative therapies be considered for patients with low or absent TPMT activity receiving azathioprine and allopurinol because both TPMT and XO inactivation pathways are affected (see CLINICAL PHARMACOLOGY, WARNINGS, PRECAUTIONS: Laboratory Tests and ADVERSE REACTIONS sections)",
        oa:prefix "Drug Interactions Use with Allopurinol ",
        oa:postfix ". Use with Aminosalicylates There is in vitro evid"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: spl:pharmgx-spl-annotation-item-9

    Annotations: 
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-9>,
        oa:hasTarget <urn:uuid:8f55dad4-8106-4b4f-a3fb-3125205241b2>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-6

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasTarget <urn:uuid:6d486688-5c78-414d-a429-2ad69ddabac2>,
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-6>
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-56

    Annotations: 
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-56>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasTarget <urn:uuid:8a673cdc-6d29-4266-b3db-24121dd35b09>
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-5

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-5>,
        oa:hasTarget <urn:uuid:a07ef183-8bab-44bf-81e8-ffbc5bbb9343>
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-57

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:hasTarget <urn:uuid:76ab2092-e671-4187-b5ce-8b208efb1d51>,
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-57>
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-8

    Annotations: 
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-8>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasTarget <urn:uuid:5f327aca-6f90-45b1-a8c9-4e93d6132568>
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-58

    Annotations: 
        oa:hasTarget <urn:uuid:3d6dab24-bd7e-46d1-bd31-243068db2feb>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-58>
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-59

    Annotations: 
        oa:hasTarget <urn:uuid:78651351-7a49-4cf6-9a6b-1a0a0fe19c87>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-59>,
        oa:annotatedAt "2013-03-13"^^xsd:date
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-7

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:hasTarget <urn:uuid:3dc3d39d-3e84-4665-897a-12cd29b9d1bf>,
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-7>
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-55

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-55>,
        oa:hasTarget <urn:uuid:624b36d7-b4af-43cf-8abb-9f8dc4e5d53f>,
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-54

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-54>,
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasTarget <urn:uuid:52efa0ca-083f-4103-95fe-bc27a2421d0e>
    
    Types: 
        oa:Annotation
    
    
Individual: <urn:uuid:9e2cd2cc-9a25-47b6-8ace-33867495d9b2>

    Annotations: 
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ab047628-67d0-4a64-8d77-36b054969b44>,
        oa:hasSelector <urn:uuid:ffefd48c-c437-4ed7-b160-d39c49de221f>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/dosageAndAdministration>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:c5ef61eb-54db-41eb-85d0-c0404c112816>

    Annotations: 
        oa:prefix "nd the 2-oxo-clopidogrel intermediate metabolite. ",
        oa:postfix "ype.   A crossover study in 40 healthy subjects, ",
        oa:exact "Clopidogrel active metabolite pharmacokinetics and antiplatelet effects, as measured by ex vivo platelet aggregation assays, differ according to CYP2C19 genotype. Genetic variants of other CYP450 enzymes may also affect the formation of clopidogrel’s active metabolite. The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and *3 alleles are nonfunctional. CYP2C19*2 and *3 account for the majority of reduced function alleles in white (85%) and Asian (99%) poor metabolizers. Other alleles associated with absent or reduced metabolism are less frequent, and include, but are not limited to, CYP2C19*4, *5, *6, *7, and *8. A patient with poor metabolizer status will possess two loss-of-function alleles as defined above. Published frequencies for poor CYP2C19 metabolizer genotypes are approximately 2% for whites, 4% for blacks and 14% for Chinese. Tests are available to determine a patient’s CYP2C19 genot"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:4a50732e-1578-4298-9c62-9f42ed2550c9>

    Annotations: 
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=040d010a-b1b2-4db7-905d-8aa7f1bab0cd>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/adverseReactions>,
        oa:hasSelector <urn:uuid:94495cce-be72-407a-907d-173c224e211a>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: spl:pharmgx-spl-annotation-item-53

    Annotations: 
        oa:hasTarget <urn:uuid:26153aed-9c18-40a6-9f56-1e98c6236d18>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-53>,
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-52

    Annotations: 
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-52>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasTarget <urn:uuid:e2dd5095-0b2d-4923-ba2a-0ddcd41d0ee7>
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-51

    Annotations: 
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-51>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:hasTarget <urn:uuid:b75f0016-423e-4d4b-8dbb-99223ce8381a>,
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-50

    Annotations: 
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-50>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasTarget <urn:uuid:b098c628-06d7-4f64-a246-230f02867738>
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-body-67

    Annotations: 
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DoseSelectionRecommendation>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2D6",
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "CODEINE",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2D6>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00318>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        spl:DoseSelectionRecommendation <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended>
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: <urn:uuid:91026743-fb76-4773-908e-9debcb491286>

    Annotations: 
        oa:prefix "tabolizers [see Dosage and Administration (2.3)]. ",
        oa:exact "WARNING: DIMINISHED EFFECTIVENESS IN POOR METABOLIZERS   See full prescribing information for complete boxed warning.   Effectiveness of clopidogrel bisulfate depends on activation to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19. (5.1) Poor metabolizers treated with clopidogrel bisulfate at recommended doses exhibit higher cardiovascular event rates following acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) than patients with normal CYP2C19 function. (12.5) Tests are available to identify a patient's CYP2C19 genotype and can be used as an aid in determining therapeutic strategy. (12.5) Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers. (2.3, 5.",
        oa:postfix "1)"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: spl:pharmgx-spl-annotation-body-66

    Annotations: 
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DoseSelectionRecommendation>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2D6",
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "CODEINE",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2D6>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00318>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        spl:DoseSelectionRecommendation <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended>
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-69

    Annotations: 
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2C9>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DoseSelectionRecommendation>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Warfarin>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00682>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        spl:DoseSelectionRecommendation <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "WARFARIN",
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2C9"
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: <urn:uuid:7017174c-c35d-4705-b332-942c590508b5>

    Annotations: 
        oa:prefix "------------------- 5.1 Hypersensitivity Reaction ",
        oa:exact "Serious and sometimes fatal hypersensitivity reactions have been associated with ZIAGEN and other abacavir-containing products. Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir. Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of a hypersensitivity reaction. Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir. For HLA-B*5701-positive patients, treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances when the potential benefit outweighs the risk.",
        oa:postfix " HLA-B*5701-negative patients may develop a hypers"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:75eb6545-f4fb-46e0-aacc-69757039f3d6>

    Annotations: 
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/drugInteractions>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=49212741-389f-4112-94a9-d14ea2115825>,
        oa:hasSelector <urn:uuid:1c463913-d31f-46c9-959c-ad94b94531b0>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: spl:pharmgx-spl-annotation-body-68

    Annotations: 
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DoseSelectionRecommendation>,
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2C9>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Warfarin>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00682>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        spl:DoseSelectionRecommendation <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "WARFARIN",
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2C9"
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: <urn:uuid:225fe84d-6164-4a12-a784-e2bd5fc0a10a>

    Annotations: 
        oa:exact "5.1 Diminished Antiplatelet Activity Due to Impaired CYP2C19 Function Clopidogrel is a prodrug. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. The metabolism of clopidogrel to its active metabolite can be impaired by genetic variations in CYP2C19 [see Boxed Warning] and by concomitant medications that interfere with CYP2C19. Avoid concomitant use of Plavix and drugs that inhibit CYP2C19 activity. Co-administration of Plavix with omeprazole, a proton pump inhibitor that is an inhibitor of CYP2C19, reduces the pharmacological activity of Plavix if given concomitantly or if given 12 hours apart [see Drug Interactions (7.1)",
        oa:postfix "]. 5.2 General Risk of Bleeding Thienopyridines, i",
        oa:prefix "eported with Plavix, including fatal cases. (5.5) "
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:5adc358c-b78a-4ebe-9f16-6e80c9eefef1>

    Annotations: 
        oa:prefix "DOSAGE AND ADMINISTRATION ",
        oa:postfix " Renal Homotransplantation The dose of azathioprin",
        oa:exact "TPMT TESTING CANNOT SUBSTITUTE FOR COMPLETE BLOOD COUNT (CBC) MONITORING IN PATIENTS RECEIVING AZATHIOPRINE TABLETS. TPMT genotyping or phenotyping can be used to identify patients with absent or reduced TPMT activity. Patients with low or absent TPMT activity are at an increased risk of developing severe, life-threatening myelotoxicity from azathioprine tablets if conventional doses are given. Physicians may consider alternative therapies for patients who have low or absent TPMT activity (homozygous for non-functional alleles). Azathioprine tablets should be administered with caution to patients having one non-functional allele (heterozygous) who are at risk for reduced TPMT activity that may lead to toxicity if conventional doses are given. Dosage reduction is recommended in patients with reduced TPMT activity. Early drug discontinuation may be considered in patients with abnormal CBC results that do not respond to dose reduction."
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:437f3d86-7c6b-48a0-b74c-b61fb1c25aac>

    Annotations: 
        oa:exact "Table 1 displays three ranges of expected maintenance warfarin sodium doses observed in subgroups of patients having different combinations of CYP2C9 and VKORC1 gene variants [see Clinical Pharmacology (12.5)]. If the patient's CYP2C9 and/or VKORC1 genotype are known, consider these ranges in choosing the initial dose. Patients with CYP2C9 *1/*3, *2/*2, *2/*3, and *3/*3 may require more prolonged time (>2 to 4 weeks) to achieve maximum INR effect for a given dosage regimen than patients without these CYP variants.",
        oa:postfix " 2.4 Monitoring to Achieve Optimal Anticoagulation",
        oa:prefix "ng Recommendations with Consideration of Genotype "
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:af81e7c7-89e3-48f5-81f7-a4f807625195>

    Annotations: 
        oa:postfix " 2.4 Use with Proton Pump Inhibitors (PPI) Avoid u",
        oa:prefix "armacology (12.3)]. 2.3 CYP2C19 Poor Metabolizers ",
        oa:exact "CYP2C19 poor metabolizer status is associated with diminished antiplatelet response to clopidogrel. Although a higher dose regimen in poor metabolizers increases antiplatelet response [see Clinical Pharmacology (12.5)], an appropriate dose regimen for this patient population has not been established."
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:2f10322f-f15f-4bc9-b4b7-8746fabef387>

    Annotations: 
        oa:prefix "tabolizers [see Dosage and Administration (2.3)]. ",
        oa:exact "WARNING: DIMINISHED EFFECTIVENESS IN POOR METABOLIZERS   See full prescribing information for complete boxed warning.   Effectiveness of clopidogrel bisulfate depends on activation to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19. (5.1) Poor metabolizers treated with clopidogrel bisulfate at recommended doses exhibit higher cardiovascular event rates following acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) than patients with normal CYP2C19 function. (12.5) Tests are available to identify a patient's CYP2C19 genotype and can be used as an aid in determining therapeutic strategy. (12.5) Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers. (2.3, 5.",
        oa:postfix "1)"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: spl:pharmgx-spl-annotation-body-60

    Annotations: 
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "CLOPIDOGREL",
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2C19",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Clopidogrel>,
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2C19>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        spl:DrugSelectionRecommendation <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00758>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugSelectionRecommendation>
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: <urn:uuid:a1083ebf-25a2-4f79-8868-79f4c9727827>

    Annotations: 
        oa:postfix " 5.10 Driving and Operating Machinery Patients sho",
        oa:prefix "settings. 5.9 Ultra-Rapid Metabolizers of Codeine ",
        oa:exact "Some individuals may be ultra-rapid metabolizers due to a specific CYP2D6*2x2 genotype. These individuals convert codeine into its active metabolite, morphine, more rapidly and completely than other people. This rapid conversion results in higher than expected serum morphine levels. Even at labeled dosage regimens, individuals who are ultra-rapid metabolizers may experience overdose symptoms such as extreme sleepiness, confusion, or shallow breathing. The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese and Japanese, 0.5 to 1% in Hispanics, 1 to 10% in Caucasians, 3% in African Americans, and 16 to 28% in North Africans, Ethiopians, and Arabs. Data are not available for other ethnic groups. When physicians prescribe codeine-containing drugs, they should choose the lowest effective dose for the shortest period of time and inform their patients about these risks and the signs of morphine overdose. [see 8 USE IN SPECIFIC POPULATIONS]"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:18656609-c71d-46f6-b2a6-22bbfebbc4e2>

    Annotations: 
        oa:exact "Warfarin sodium is a narrow therapeutic range (index) drug, and additional caution should be observed when warfarin sodium is administered to certain patients. Reported risk factors for bleeding include high intensity of anticoagulation (INR >4), age >65, highly variable INRs, history of gastrointestinal bleeding, hypertension, cerebrovascular disease, serious heart disease, anemia, malignancy, trauma, renal insufficiency, concomitant drugs (see PRECAUTIONS), and long duration of warfarin therapy. Identification of risk factors for bleeding and certain genetic variations in CYP2CP and VKORC1 in a patient may increase the need for more frequent INR monitoring and the use of lower warfarin doses (see CLINICAL PHARMACOLOGY, Pharmacokinetics, Metabolism and DOSAGE AND ADMINISTRATION). Bleeding is more likely to occur during the starting period and with a higher dose of warfarin sodium (resulting in a higher INR)",
        oa:postfix ". Intramuscular (IM) injections of concomitant med",
        oa:prefix "etion. Considerations for Increased Bleeding Risk "
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: spl:pharmgx-spl-annotation-body-61

    Annotations: 
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DoseSelectionRecommendation>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2D6",
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB01238>,
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2D6>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        spl:DoseSelectionRecommendation <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "ARIPIPRAZOLE"
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-62

    Annotations: 
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DoseSelectionRecommendation>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2D6",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2D6>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB01238>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        spl:DoseSelectionRecommendation <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "ARIPIPRAZOLE"
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-63

    Annotations: 
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DoseSelectionRecommendation>,
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Azathioprine>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "AZATHIOPRINE",
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00993>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        spl:DoseSelectionRecommendation <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "TPMT"
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-64

    Annotations: 
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DoseSelectionRecommendation>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "AZATHIOPRINE",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Azathioprine>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00993>,
        spl:DoseSelectionRecommendation <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "TPMT"
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-65

    Annotations: 
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DoseSelectionRecommendation>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "CITALOPRAM",
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2C19",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2C19>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00215>,
        spl:DoseSelectionRecommendation <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended>
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: <urn:uuid:384a4f55-72b6-46e4-9079-1bfffc353193>

    Annotations: 
        oa:hasSelector <urn:uuid:fe9b09c6-181b-4d57-87a7-f4c68c3dbbdb>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7500c65e-9680-4719-b426-90a7162352c9>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinicalPharmacology>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: spl:pharmgx-spl-annotation-item-49

    Annotations: 
        oa:hasTarget <urn:uuid:928c5b11-9b22-4cd7-8d3c-e4a2a134d0df>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-49>
    
    Types: 
        oa:Annotation
    
    
Individual: <urn:uuid:8da4db8d-c421-40a1-9802-57b8d2163229>

    Annotations: 
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c3248d43-3dd6-4ca9-afca-528c7abe0fce>,
        oa:hasSelector <urn:uuid:2e806231-c922-4f27-819c-7295e463e529>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinicalPharmacology>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:ce93ba8e-ecca-4761-af1c-e91d82dd6f53>

    Annotations: 
        oa:prefix "ocytic anemia and/or bleeding have been reported. ",
        oa:exact "TPMT genotyping or phenotyping can help identify patients with low or absent TPMT activity (homozygous for non-functional alleles) who are at increased risk for severe, life-threatening myelosuppression from azathioprine tablets (see CLINICAL PHARMACOLOGY, WARNINGS and PRECAUTIONS: Laboratory Tests). Death associated with pancytopenia has been reported in patients with absent TPMT activity receiving azathioprine.6, 20",
        oa:postfix " Gastrointestinal Nausea and vomiting may occur wi"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: spl:pharmgx-spl-annotation-item-47

    Annotations: 
        oa:hasTarget <urn:uuid:d73cbc6e-3847-4fd3-837b-ee3f14abfc85>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-47>,
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-48

    Annotations: 
        oa:hasTarget <urn:uuid:03bd6e72-f790-49a2-ac80-79350e03f241>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-48>
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-45

    Annotations: 
        oa:hasTarget <urn:uuid:9bf90051-9a72-43ee-bca7-c28bdf625a80>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-45>,
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-46

    Annotations: 
        oa:hasTarget <urn:uuid:011d66ae-2e94-4e6f-a4b1-1612179546bd>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-46>
    
    Types: 
        oa:Annotation
    
    
Individual: <urn:uuid:76ab2092-e671-4187-b5ce-8b208efb1d51>

    Annotations: 
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=128846a7-18c6-4bc4-b3a0-9aeed0e8b986>,
        oa:hasSelector <urn:uuid:2e332e4e-ee0b-4b7e-a8a8-fda9887c4f4e>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/dosageAndAdministration>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:7047bb6e-0cbc-4ecf-adbb-ee3dbead12d5>

    Annotations: 
        oa:exact "Azathioprine is metabolized to 6-mercaptopurine (6-MP). Both compounds are rapidly eliminated from blood and are oxidized or methylated in erythrocytes and liver; no azathioprine or mercaptopurine is detectable in urine after 8 hours. Activation of 6-mercaptopurine occurs via hypoxanthine-guanine phosphoribosyltransferase (HGPRT) and a series of multi-enzymatic processes involving kinases to form 6-thioguanine nucleotides (6TGNs) as major metabolites (See Metabolism Scheme in Figure 1). The cytotoxicity of azathioprine is due, in part, to the incorporation of 6-TGN into DNA. 6-MP undergoes two major inactivation routes (Figure 1). One is thiol methylation, which is catalyzed by the enzyme thiopurine S-methyltransferase (TPMT), to form the inactive metabolite methyl-6-MP (6-MeMP). TPMT activity is controlled by a genetic polymorphism. 1,2,3 For Caucasians and African Americans, approximately 10% of the population inherit one non-functional TPMT allele (heterozygous) conferring intermediate TPMT activity, and 0.3% inherit two TPMT non-functional alleles (homozygous) for low or absent TPMT activity. Non-functional alleles are less common in Asians. TPMT activity correlates inversely with 6TGN levels in erythrocytes and presumably other hematopoietic tissues, since these cells have negligible xanthine oxidase (involved in the other inactivation pathway) activities, leaving TPMT methylation as the only inactivation pathway. Patients with intermediate TPMT activity may be at increased risk of myelotoxicity if receiving conventional doses of azathioprine. Patients with low or absent TPMT activity are at an increased risk of developing severe, life-threatening myelotoxicity if receiving conventional doses of azathioprine.4-9 TPMT genotyping or phenotyping (red blood cell TPMT activity) can help identify patients who are at an increased risk for developing azathioprine toxicity.2, 3, 7, 8, 9 Accurate phenotyping (red blood cell TPMT activity) results are not possible in patients who have received recent blood transfusions. (See WARNINGS, PRECAUTIONS: Drug Interactions, PRECAUTIONS: Laboratory Tests and ADVERSE REACTIONS sections)",
        oa:postfix ". Figure 1. Metabolism pathway of azathioprine : c",
        oa:prefix " and are partially dialyzable. (See OVERDOSAGE ). "
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:36edf6a8-3df6-4e0b-af82-7eaf73a6128c>

    Annotations: 
        oa:prefix "settings. 5.9 Ultra-Rapid Metabolizers of Codeine ",
        oa:postfix " 5.10 Driving and Operating Machinery Patients sho",
        oa:exact "Some individuals may be ultra-rapid metabolizers due to a specific CYP2D6*2x2 genotype. These individuals convert codeine into its active metabolite, morphine, more rapidly and completely than other people. This rapid conversion results in higher than expected serum morphine levels. Even at labeled dosage regimens, individuals who are ultra-rapid metabolizers may experience overdose symptoms such as extreme sleepiness, confusion, or shallow breathing. The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese and Japanese, 0.5 to 1% in Hispanics, 1 to 10% in Caucasians, 3% in African Americans, and 16 to 28% in North Africans, Ethiopians, and Arabs. Data are not available for other ethnic groups. When physicians prescribe codeine-containing drugs, they should choose the lowest effective dose for the shortest period of time and inform their patients about these risks and the signs of morphine overdose. [see 8 USE IN SPECIFIC POPULATIONS]"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:60698153-8e21-4917-a112-4cc020788bf0>

    Annotations: 
        oa:prefix "presents about 40% of aripiprazole AUC in plasma. ",
        oa:postfix " Following a single oral dose of [14C]-labeled ari",
        oa:exact "Approximately 8% of Caucasians lack the capacity to metabolize CYP2D6 substrates and are classified as poor metabolizers (PM), whereas the rest are extensive metabolizers (EM). PMs have about an 80% increase in aripiprazole exposure and about a 30% decrease in exposure to the active metabolite compared to EMs, resulting in about a 60% higher exposure to the total active moieties from a given dose of aripiprazole compared to EMs. Coadministration of ABILIFY with known inhibitors of CYP2D6, such as quinidine or fluoxetine in EMs, approximately doubles aripiprazole plasma exposure, and dose adjustment is needed [see DRUG INTERACTIONS (7.1)]. The mean elimination half-lives are about 75 hours and 146 hours for aripiprazole in EMs and PMs, respectively. Aripiprazole does not inhibit or induce the CYP2D6 pathway."
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: spl:pharmgx-spl-annotation-body-59

    Annotations: 
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "AZATHIOPRINE",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Azathioprine>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        spl:DrugSelectionRecommendation <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00993>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "TPMT",
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugSelectionRecommendation>
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-58

    Annotations: 
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "AZATHIOPRINE",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Azathioprine>,
        spl:DrugSelectionRecommendation <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#discontinue>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00993>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "TPMT",
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugSelectionRecommendation>
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-57

    Annotations: 
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "AZATHIOPRINE",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Azathioprine>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        spl:DrugSelectionRecommendation <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00993>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "TPMT",
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugSelectionRecommendation>
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-56

    Annotations: 
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB01048>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "ABACAVIR",
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "HLA-B*5701",
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugSelectionRecommendation>,
        spl:DrugSelectionRecommendation <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-restart>
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-55

    Annotations: 
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB01048>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        spl:DrugSelectionRecommendation <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "ABACAVIR",
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugSelectionRecommendation>,
        spl:DrugSelectionRecommendation <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-restart>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "HLA-B*5701"
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: <urn:uuid:86748657-bab4-48d1-80da-dac9242628ca>

    Annotations: 
        oa:hasSelector <urn:uuid:850a3758-6d57-43b7-b00f-7031d9cc91af>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ab047628-67d0-4a64-8d77-36b054969b44>,
        oa:hasSelector <urn:uuid:437f3d86-7c6b-48a0-b74c-b61fb1c25aac>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/dosageAndAdministration>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: spl:pharmgx-spl-annotation-body-53

    Annotations: 
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2D6",
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "CODEINE",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2D6>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#VariantFrequency>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        spl:VariantFrequency <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00318>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-54

    Annotations: 
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2C9>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#VariantFrequency>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Warfarin>,
        spl:VariantFrequency <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00682>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "WARFARIN",
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2C9"
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-51

    Annotations: 
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "CLOPIDOGREL",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Clopidogrel>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2C19",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2C19>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#VariantFrequency>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        spl:VariantFrequency <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00758>
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-52

    Annotations: 
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2D6",
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "CODEINE",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2D6>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#VariantFrequency>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        spl:VariantFrequency <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00318>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-50

    Annotations: 
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Azathioprine>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "AZATHIOPRINE",
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#VariantFrequency>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        spl:VariantFrequency <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00993>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "TPMT"
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: <urn:uuid:8f55dad4-8106-4b4f-a3fb-3125205241b2>

    Annotations: 
        oa:hasSelector <urn:uuid:b9bbb66e-7a10-49fb-91e4-9a2c7b770e73>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=16bda7b5-a5a5-4478-9df3-beb396bd677f>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/warnings>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:c151b711-e27a-441f-9a45-eda717e46232>

    Annotations: 
        oa:postfix " Therapeutic doses of warfarin decrease the total ",
        oa:exact "Warfarin is thought to interfere with clotting factor synthesis by inhibition of the C1 subunit of the vitamin K epoxide reductase (VKORC1) enzyme complex, thereby reducing the regeneration of vitamin K1 epoxide. The degree of depression is dependent upon the dosage administered and, in part, by the patient's VKORC1 genotype.",
        oa:prefix "tial for biological activity. Mechanism of Action "
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:8d4ed9d2-0ab1-4f63-93c1-0415fb189c06>

    Annotations: 
        oa:exact "Azathioprine tablets should be administered with caution to patients having one non-functional allele (heterozygous) who are at risk for reduced TPMT activity that may lead to toxicity if conventional doses are given. Dosage reduction is recommended in patients with reduced TPMT activity. Early drug discontinuation may be considered in patients with abnormal CBC results that do not respond to dose reduction.",
        oa:prefix "activity (homozygous for non-functional alleles). ",
        oa:postfix " Renal Homotransplantation The dose of azathioprin"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:b098c628-06d7-4f64-a246-230f02867738>

    Annotations: 
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7500c65e-9680-4719-b426-90a7162352c9>,
        oa:hasSelector <urn:uuid:6bff9d47-ca18-4047-8e7f-2523fb3108c5>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinicalPharmacology>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:ecd730fc-6095-4549-8bdf-a6d437097f73>

    Annotations: 
        oa:exact "Citalopram causes dose-dependent QTc prolongation, an ECG abnormality that has been associated with torsade de pointes (TdP), ventricular tachycardia, and sudden death, all of which have been observed in postmarketing reports for citalopram. Individually corrected QTc (QTcNi) interval was evaluated in a randomized, placebo and active (moxifloxacin 400 mg) controlled cross-over, escalating multiple-dose study in 119 healthy subjects. The maximum mean (upper bound of the 95% one-sided confidence interval) difference from placebo were 8.5 (10.8) and 18.5 (21.0) msec for 20 mg and 60 mg citalopram, respectively. Based on the established exposure-response relationship, the predicted QTcNi change from placebo (upper bound of the 95% one-sided confidence interval) under the Cmax for the dose of 40 mg is 12.6 (14.3) msec. Because of the risk of QTc prolongation at higher citalopram doses, it is recommended that citalopram should not be given at doses above 40 mg/day. It is recommended that citalopram should not be used in patients with congenital long QT syndrome, bradycardia, hypokalemia or hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure. Citalopram should also not be used in patients who are taking other drugs that prolong the QTc interval. Such drugs include Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications, antipsychotic medications (e.g., chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to prolong the QTc interval (e.g., pentamidine, levomethadyl acetate, methadone). The citalopram dose should be limited in certain populations. The maximum dose should be limited to 20 mg/day in patients who are CYP2C19 poor metabolizers or those patients who may be taking concomitant cimetidine or another CYP2C19 inhibitor, since higher citalopram exposures would be expected. The maximum dose should also be limited to 20 mg/day in patients with hepatic impairment and in patients who are greater than 60 years of age because of expected higher exposures.",
        oa:prefix " overdose. QT-Prolongation and Torsade de Pointes ",
        oa:postfix " Electrolyte and/or ECG monitoring is recommended "
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: spl:pharmgx-spl-annotation-item-71

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-71>,
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasTarget <urn:uuid:9cf2b3b9-3dab-4b9e-90a4-15df8790504b>
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-70

    Annotations: 
        oa:hasTarget <urn:uuid:36d9a9a3-d77b-443f-98d4-cc437ad35826>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-70>
    
    Types: 
        oa:Annotation
    
    
Individual: <urn:uuid:3d6dab24-bd7e-46d1-bd31-243068db2feb>

    Annotations: 
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=128846a7-18c6-4bc4-b3a0-9aeed0e8b986>,
        oa:hasSelector <urn:uuid:8d4ed9d2-0ab1-4f63-93c1-0415fb189c06>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/dosageAndAdministration>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: <urn:uuid:ffa36f01-b3f5-47ae-ae5d-cb5a19daf790>

    Annotations: 
        oa:hasSelector <urn:uuid:a78aaafc-795e-4649-9686-5f4ab8e2f1f2>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/useInSpecificPopulations>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa3ed180-298a-4f9d-9d05-15182d7218bf>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: spl:pharmgx-spl-annotation-body-49

    Annotations: 
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2D6",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2D6>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB01238>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#VariantFrequency>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        spl:VariantFrequency <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "ARIPIPRAZOLE"
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-48

    Annotations: 
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2C9>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Warfarin>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00682>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        spl:PharmacokineticImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "WARFARIN",
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2C9"
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: <urn:uuid:a78aaafc-795e-4649-9686-5f4ab8e2f1f2>

    Annotations: 
        oa:postfix "S] 8.4 Pediatric Use The safety and effectiveness ",
        oa:prefix "nduced respiratory depression in the neonate. 8.3 ",
        oa:exact "Nursing Mothers Codeine is secreted into human milk. In women with normal codeine metabolism (normal CYP2D6 activity), the amount of codeine secreted into human milk is low and dose-dependent. However, some women are ultra-rapid metabolizers of codeine. These women achieve higher-than-expected serum levels of codeine’s active metabolite, morphine, leading to higher-than-expected levels of morphine in breast milk and potentially dangerously high serum morphine levels in their breastfed infants. Therefore, maternal use of codeine can potentially lead to serious adverse reactions, including death, in nursing infants. The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese and Japanese, 0.5 to 1% in Hispanics, 1 to 10% in Caucasians, 3% in African Americans, and 16 to 28% in North Africans, Ethiopians, and Arabs. Data are not available for other ethnic groups. The risk of infant exposure to codeine and morphine through breast milk should be weighed against the benefits of breastfeeding for both the mother and the baby. Caution should be exercised when codeine is administered to a nursing woman. If a codeine containing product is selected, the lowest dose should be prescribed for the shortest period of time to achieve the desired clinical effect. Mothers using codeine should be informed about when to seek immediate medical care and how to identify the signs and symptoms of neonatal toxicity, such as drowsiness or sedation, difficulty breastfeeding, breathing difficulties, and decreased tone, in their baby. Nursing mothers who are ultra-rapid metabolizers may also experience overdose symptoms such as extreme sleepiness, confusion, or shallow breathing. Prescribers should closely monitor mother-infant pairs and notify treating pediatricians about the use of codeine during breastfeeding. [see 5 WARNINGS AND PRECAUTION"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:e86f13d0-b9d2-457b-baec-807a8111ffd9>

    Annotations: 
        oa:prefix "presents about 40% of aripiprazole AUC in plasma. ",
        oa:postfix " Following a single oral dose of [14C]-labeled ari",
        oa:exact "Approximately 8% of Caucasians lack the capacity to metabolize CYP2D6 substrates and are classified as poor metabolizers (PM), whereas the rest are extensive metabolizers (EM). PMs have about an 80% increase in aripiprazole exposure and about a 30% decrease in exposure to the active metabolite compared to EMs, resulting in about a 60% higher exposure to the total active moieties from a given dose of aripiprazole compared to EMs. Coadministration of ABILIFY with known inhibitors of CYP2D6, such as quinidine or fluoxetine in EMs, approximately doubles aripiprazole plasma exposure, and dose adjustment is needed [see DRUG INTERACTIONS (7.1)]. The mean elimination half-lives are about 75 hours and 146 hours for aripiprazole in EMs and PMs, respectively. Aripiprazole does not inhibit or induce the CYP2D6 pathway."
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: spl:pharmgx-spl-annotation-body-45

    Annotations: 
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2D6",
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "CODEINE",
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>,
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2D6>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00318>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        spl:PharmacokineticImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase>
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: <urn:uuid:fc44cf07-fcf4-44ff-9c08-0b8e237e9974>

    Annotations: 
        oa:exact "Clopidogrel  bisulfate at recommended doses forms less of that metabolite and has a smaller effect on platelet function in patients who are CYP2C19 poor metabolizers.  Poor metabolizers with acute coronary syndrome or undergoing percutaneous coronary intervention treated with clopidogrel bisulfate at recommended doses exhibit higher cardiovascular event rates than do patients with normal CYP2C19 function. Tests are available to identify a patient's CYP2C19 genotype; these tests can be used as an aid in determining therapeutic strategy [see Clinical Pharmacology (12.5)]. Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers [see Dosage and Administration",
        oa:postfix " (2.3)]. WARNING: DIMINISHED EFFECTIVENESS IN POOR",
        oa:prefix "lly CYP2C19 [see Warnings and Precautions (5.1)]. "
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:624b36d7-b4af-43cf-8abb-9f8dc4e5d53f>

    Annotations: 
        oa:hasSelector <urn:uuid:b8ceec74-9cde-4e04-8472-210c94991453>,
        oa:hasSelector <urn:uuid:8adfb52c-bb5e-411c-859c-bcf62b921dc3>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/warningsAndPrecautions>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
Individual: spl:pharmgx-spl-annotation-body-44

    Annotations: 
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "CLOPIDOGREL",
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>,
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Clopidogrel>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2C19",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2C19>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        spl:PharmacokineticImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00758>
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-47

    Annotations: 
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2C9>,
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Warfarin>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00682>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        spl:PharmacokineticImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "WARFARIN",
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2C9"
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-46

    Annotations: 
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2D6",
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "CODEINE",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2D6>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00318>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        spl:PharmacokineticImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase>
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-40

    Annotations: 
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "CITALOPRAM",
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2C19",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2C19>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00215>,
        spl:PharmacokineticImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease>
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-41

    Annotations: 
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "CLOPIDOGREL",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Clopidogrel>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2C19",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2C19>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        spl:PharmacokineticImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00758>
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-42

    Annotations: 
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "CLOPIDOGREL",
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2C19",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Clopidogrel>,
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2C19>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        spl:PharmacokineticImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00758>
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: spl:pharmgx-spl-annotation-body-43

    Annotations: 
        <http://semanticscience.org/resource/SIO_000563> <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacokineticImpact>,
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug> "CLOPIDOGREL",
        <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker> "CYP2C19",
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#Clopidogrel>,
        rdfs:seeAlso <http://www.genomic-cds.org/ont/genomic-cds.owl#CYP2C19>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxDrug>,
        <http://semanticscience.org/resource/SIO_000628> <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pharmgxBiomarker>,
        spl:PharmacokineticImpact <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease>,
        rdfs:seeAlso <http://bio2rdf.org/drugbank:DB00758>
    
    Types: 
        spl:PharmacogenomicsStatement
    
    
Individual: <urn:uuid:ffefd48c-c437-4ed7-b160-d39c49de221f>

    Annotations: 
        oa:postfix " 2.4 Monitoring to Achieve Optimal Anticoagulation",
        oa:prefix "ical maintenance doses are 2 to 10 mg once daily. ",
        oa:exact "Dosing Recommendations with Consideration of Genotype Table 1 displays three ranges of expected maintenance warfarin sodium doses observed in subgroups of patients having different combinations of CYP2C9 and VKORC1 gene variants [see Clinical Pharmacology (12.5)]. If the patient's CYP2C9 and/or VKORC1 genotype are known, consider these ranges in choosing the initial dose. Patients with CYP2C9 *1/*3, *2/*2, *2/*3, and *3/*3 may require more prolonged time (>2 to 4 weeks) to achieve maximum INR effect for a given dosage regimen than patients without these CYP variants."
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: <urn:uuid:f7a7d71c-cb3e-47d8-877e-1bbb7ae9825c>

    Annotations: 
        oa:prefix "01 status who have previously tolerated abacavir. ",
        oa:exact "For HLA-B*5701-positive patients, treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances when the potential benefit outweighs the risk.",
        oa:postfix " HLA-B*5701-negative patients may develop a hypers"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: spl:pharmgx-spl-annotation-item-69

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:hasTarget <urn:uuid:84cfe968-4129-4a76-9295-b2ae6b5d65d0>,
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-69>
    
    Types: 
        oa:Annotation
    
    
Individual: spl:pharmgx-spl-annotation-item-67

    Annotations: 
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-67>,
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:hasTarget <urn:uuid:fb3f4b4b-f0b6-43f1-99e0-86459c27c00c>,
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date
    
    Types: 
        oa:Annotation
    
    
Individual: <urn:uuid:1c463913-d31f-46c9-959c-ad94b94531b0>

    Annotations: 
        oa:exact "One of the pathways for inactivation of azathioprine is inhibited by allopurinol. Patients receiving azathioprine and allopurinol concomitantly should have a dose reduction of azathioprine, to approximately 1/3 to 1/4 the usual dose. It is recommended that a further dose reduction or alternative therapies be considered for patients with low or absent TPMT activity receiving azathioprine and allopurinol because both TPMT and XO inactivation pathways are affected (see CLINICAL PHARMACOLOGY, WARNINGS, PRECAUTIONS: Laboratory Tests and ADVERSE REACTIONS sections)",
        oa:prefix "Drug Interactions Use with Allopurinol ",
        oa:postfix ". Use with Aminosalicylates There is in vitro evid"
    
    Types: 
        oa:TextQuoteSelector
    
    
Individual: spl:pharmgx-spl-annotation-item-68

    Annotations: 
        oa:annotatedBy "TRIADS Lab, University of Pittsburgh",
        oa:hasTarget <urn:uuid:f2973cae-d394-44a3-a7a3-a43183bd99fc>,
        oa:motivatedBy <http://www.w3.org/ns/oa#tagging>,
        oa:annotatedAt "2013-03-13"^^xsd:date,
        oa:hasBody <http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#pharmgx-spl-annotation-body-68>
    
    Types: 
        oa:Annotation
    
    
Individual: <urn:uuid:c1b5873b-83ed-48de-95bb-4cbb216ccea5>

    Annotations: 
        oa:hasSelector <urn:uuid:293d0fa9-a023-46c6-9662-879287c1a9f2>,
        spl:SPLSection <http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/boxedWarning>,
        oa:hasSource <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d021d9b-c0b8-41a3-a99b-37f50d2a20ae>,
        oa:hasSelector <urn:uuid:2f10322f-f15f-4bc9-b4b7-8746fabef387>
    
    Types: 
        oa:SpecificResource,
        spl:SPLConstrainedTarget
    
    
